id	sid	tid	token	lemma	pos
dti-1420	1	1	9drug	9drug	NUM
dti-1420	1	2	target	target	NOUN
dti-1420	1	3	insights	insight	NOUN
dti-1420	1	4	2016:10	2016:10	NUM
dti-1420	1	5	a	a	DET
dti-1420	1	6	case	case	NOUN
dti-1420	1	7	of	of	ADP
dti-1420	1	8	organizing	organize	VERB
dti-1420	1	9	pneumonia	pneumonia	NOUN
dti-1420	1	10	(	(	PUNCT
dti-1420	1	11	op	op	NOUN
dti-1420	1	12	)	)	PUNCT
dti-1420	1	13	associated	associate	VERB
dti-1420	1	14	with	with	ADP
dti-1420	1	15	pembrolizumab	pembrolizumab	NOUN
dti-1420	1	16	paraskevi	paraskevi	ADJ
dti-1420	1	17	fragkou1	fragkou1	PROPN
dti-1420	1	18	,	,	PUNCT
dti-1420	1	19	maria	maria	PROPN
dti-1420	1	20	souli1	souli1	PROPN
dti-1420	1	21	,	,	PUNCT
dti-1420	1	22	maria	maria	PROPN
dti-1420	1	23	theochari2	theochari2	PROPN
dti-1420	1	24	,	,	PUNCT
dti-1420	1	25	christina	christina	PROPN
dti-1420	1	26	kontopoulou3	kontopoulou3	PROPN
dti-1420	1	27	,	,	PUNCT
dti-1420	1	28	stelios	stelio	NOUN
dti-1420	1	29	loukides4	loukides4	NOUN
dti-1420	1	30	and	and	CCONJ
dti-1420	1	31	anna	anna	PROPN
dti-1420	1	32	koumarianou2	koumarianou2	PROPN
dti-1420	1	33	1fourth	1fourth	NUM
dti-1420	1	34	department	department	NOUN
dti-1420	1	35	of	of	ADP
dti-1420	1	36	internal	internal	ADJ
dti-1420	1	37	medicine	medicine	NOUN
dti-1420	1	38	,	,	PUNCT
dti-1420	1	39	infectious	infectious	ADJ
dti-1420	1	40	diseases	disease	NOUN
dti-1420	1	41	unit	unit	NOUN
dti-1420	1	42	,	,	PUNCT
dti-1420	1	43	attikon	attikon	PROPN
dti-1420	1	44	university	university	NOUN
dti-1420	1	45	hospital	hospital	NOUN
dti-1420	1	46	,	,	PUNCT
dti-1420	1	47	national	national	ADJ
dti-1420	1	48	and	and	CCONJ
dti-1420	1	49	kapodistrian	kapodistrian	ADJ
dti-1420	1	50	university	university	PROPN
dti-1420	1	51	of	of	ADP
dti-1420	1	52	athens	athens	PROPN
dti-1420	1	53	,	,	PUNCT
dti-1420	1	54	athens	athens	PROPN
dti-1420	1	55	,	,	PUNCT
dti-1420	1	56	greece	greece	PROPN
dti-1420	1	57	.	.	PUNCT
dti-1420	2	1	2fourth	2fourth	NUM
dti-1420	2	2	department	department	NOUN
dti-1420	2	3	of	of	ADP
dti-1420	2	4	internal	internal	ADJ
dti-1420	2	5	medicine	medicine	NOUN
dti-1420	2	6	,	,	PUNCT
dti-1420	2	7	hematology	hematology	NOUN
dti-1420	2	8	-	-	PUNCT
dti-1420	2	9	oncology	oncology	NOUN
dti-1420	2	10	unit	unit	NOUN
dti-1420	2	11	,	,	PUNCT
dti-1420	2	12	attikon	attikon	PROPN
dti-1420	2	13	university	university	NOUN
dti-1420	2	14	hospital	hospital	NOUN
dti-1420	2	15	,	,	PUNCT
dti-1420	2	16	national	national	ADJ
dti-1420	2	17	and	and	CCONJ
dti-1420	2	18	kapodistrian	kapodistrian	ADJ
dti-1420	2	19	university	university	PROPN
dti-1420	2	20	of	of	ADP
dti-1420	2	21	athens	athens	PROPN
dti-1420	2	22	,	,	PUNCT
dti-1420	2	23	athens	athens	PROPN
dti-1420	2	24	,	,	PUNCT
dti-1420	2	25	greece	greece	PROPN
dti-1420	2	26	.	.	PUNCT
dti-1420	3	1	32nd	32nd	ADJ
dti-1420	3	2	radiology	radiology	NOUN
dti-1420	3	3	department	department	NOUN
dti-1420	3	4	,	,	PUNCT
dti-1420	3	5	attikon	attikon	ADJ
dti-1420	3	6	university	university	NOUN
dti-1420	3	7	hospital	hospital	NOUN
dti-1420	3	8	,	,	PUNCT
dti-1420	3	9	national	national	ADJ
dti-1420	3	10	and	and	CCONJ
dti-1420	3	11	kapodistrian	kapodistrian	ADJ
dti-1420	3	12	university	university	PROPN
dti-1420	3	13	of	of	ADP
dti-1420	3	14	athens	athens	PROPN
dti-1420	3	15	,	,	PUNCT
dti-1420	3	16	athens	athens	PROPN
dti-1420	3	17	,	,	PUNCT
dti-1420	3	18	greece	greece	PROPN
dti-1420	3	19	.	.	PUNCT
dti-1420	4	1	42nd	42nd	ADJ
dti-1420	4	2	respiratory	respiratory	ADJ
dti-1420	4	3	medicine	medicine	NOUN
dti-1420	4	4	department	department	PROPN
dti-1420	4	5	,	,	PUNCT
dti-1420	4	6	attikon	attikon	ADJ
dti-1420	4	7	university	university	NOUN
dti-1420	4	8	hospital	hospital	NOUN
dti-1420	4	9	,	,	PUNCT
dti-1420	4	10	national	national	ADJ
dti-1420	4	11	and	and	CCONJ
dti-1420	4	12	kapodistrian	kapodistrian	ADJ
dti-1420	4	13	university	university	PROPN
dti-1420	4	14	of	of	ADP
dti-1420	4	15	athens	athens	PROPN
dti-1420	4	16	,	,	PUNCT
dti-1420	4	17	athens	athens	PROPN
dti-1420	4	18	,	,	PUNCT
dti-1420	4	19	greece	greece	PROPN
dti-1420	4	20	.	.	PROPN
dti-1420	5	1	abstr	abstr	PROPN
dti-1420	5	2	act	act	PROPN
dti-1420	5	3	:	:	PUNCT
dti-1420	5	4	until	until	ADP
dti-1420	5	5	recently	recently	ADV
dti-1420	5	6	,	,	PUNCT
dti-1420	5	7	chemotherapy	chemotherapy	NOUN
dti-1420	5	8	for	for	ADP
dti-1420	5	9	metastatic	metastatic	ADJ
dti-1420	5	10	melanoma	melanoma	NOUN
dti-1420	5	11	had	have	VERB
dti-1420	5	12	disappointing	disappointing	ADJ
dti-1420	5	13	results	result	NOUN
dti-1420	5	14	.	.	PUNCT
dti-1420	6	1	the	the	DET
dti-1420	6	2	identification	identification	NOUN
dti-1420	6	3	of	of	ADP
dti-1420	6	4	immune	immune	ADJ
dti-1420	6	5	checkpoints	checkpoint	NOUN
dti-1420	6	6	such	such	ADJ
dti-1420	6	7	as	as	ADP
dti-1420	6	8	ctla-4	ctla-4	NUM
dti-1420	6	9	and	and	CCONJ
dti-1420	6	10	pd-1	pd-1	ADJ
dti-1420	6	11	/	/	SYM
dti-1420	6	12	pd	pd	NOUN
dti-1420	6	13	-	-	PROPN
dti-1420	6	14	l1	l1	PROPN
dti-1420	6	15	has	have	AUX
dti-1420	6	16	led	lead	VERB
dti-1420	6	17	to	to	ADP
dti-1420	6	18	the	the	DET
dti-1420	6	19	development	development	NOUN
dti-1420	6	20	of	of	ADP
dti-1420	6	21	an	an	DET
dti-1420	6	22	array	array	NOUN
dti-1420	6	23	of	of	ADP
dti-1420	6	24	monoclonal	monoclonal	NOUN
dti-1420	6	25	antibodies	antibody	NOUN
dti-1420	6	26	(	(	PUNCT
dti-1420	6	27	mabs	mab	NOUN
dti-1420	6	28	)	)	PUNCT
dti-1420	6	29	.	.	PUNCT
dti-1420	7	1	these	these	DET
dti-1420	7	2	immunologic	immunologic	ADJ
dti-1420	7	3	approaches	approach	NOUN
dti-1420	7	4	against	against	ADP
dti-1420	7	5	tumoral	tumoral	ADJ
dti-1420	7	6	cells	cell	NOUN
dti-1420	7	7	come	come	VERB
dti-1420	7	8	with	with	ADP
dti-1420	7	9	a	a	DET
dti-1420	7	10	novel	novel	ADJ
dti-1420	7	11	kind	kind	NOUN
dti-1420	7	12	of	of	ADP
dti-1420	7	13	side	side	NOUN
dti-1420	7	14	effects	effect	NOUN
dti-1420	7	15	that	that	PRON
dti-1420	7	16	the	the	DET
dti-1420	7	17	clinician	clinician	NOUN
dti-1420	7	18	needs	need	VERB
dti-1420	7	19	to	to	PART
dti-1420	7	20	be	be	AUX
dti-1420	7	21	familiarized	familiarize	VERB
dti-1420	7	22	with	with	ADP
dti-1420	7	23	.	.	PUNCT
dti-1420	8	1	herein	herein	NOUN
dti-1420	8	2	,	,	PUNCT
dti-1420	8	3	we	we	PRON
dti-1420	8	4	report	report	VERB
dti-1420	8	5	for	for	ADP
dti-1420	8	6	the	the	DET
dti-1420	8	7	first	first	ADJ
dti-1420	8	8	time	time	NOUN
dti-1420	8	9	a	a	DET
dti-1420	8	10	case	case	NOUN
dti-1420	8	11	of	of	ADP
dti-1420	8	12	organizing	organize	VERB
dti-1420	8	13	pneumonia	pneumonia	NOUN
dti-1420	8	14	,	,	PUNCT
dti-1420	8	15	based	base	VERB
dti-1420	8	16	on	on	ADP
dti-1420	8	17	imaging	imaging	NOUN
dti-1420	8	18	and	and	CCONJ
dti-1420	8	19	cytological	cytological	ADJ
dti-1420	8	20	analyses	analysis	NOUN
dti-1420	8	21	of	of	ADP
dti-1420	8	22	bronchoalveolar	bronchoalveolar	ADJ
dti-1420	8	23	lavage	lavage	NOUN
dti-1420	8	24	,	,	PUNCT
dti-1420	8	25	possibly	possibly	ADV
dti-1420	8	26	associated	associate	VERB
dti-1420	8	27	with	with	ADP
dti-1420	8	28	the	the	DET
dti-1420	8	29	use	use	NOUN
dti-1420	8	30	of	of	ADP
dti-1420	8	31	pembrolizumab	pembrolizumab	NOUN
dti-1420	8	32	,	,	PUNCT
dti-1420	8	33	an	an	DET
dti-1420	8	34	anti	anti	ADJ
dti-1420	8	35	-	-	ADJ
dti-1420	8	36	pd-1	pd-1	ADJ
dti-1420	8	37	mab	mab	NOUN
dti-1420	8	38	recently	recently	ADV
dti-1420	8	39	approved	approve	VERB
dti-1420	8	40	for	for	ADP
dti-1420	8	41	the	the	DET
dti-1420	8	42	treatment	treatment	NOUN
dti-1420	8	43	of	of	ADP
dti-1420	8	44	metastatic	metastatic	ADJ
dti-1420	8	45	melanoma	melanoma	NOUN
dti-1420	8	46	.	.	PUNCT
dti-1420	9	1	key	key	ADJ
dti-1420	9	2	words	word	NOUN
dti-1420	9	3	:	:	PUNCT
dti-1420	9	4	op	op	NOUN
dti-1420	9	5	,	,	PUNCT
dti-1420	9	6	organizing	organize	VERB
dti-1420	9	7	pneumonia	pneumonia	NOUN
dti-1420	9	8	,	,	PUNCT
dti-1420	9	9	pembrolizumab	pembrolizumab	NOUN
dti-1420	9	10	,	,	PUNCT
dti-1420	9	11	melanoma	melanoma	NOUN
dti-1420	9	12	,	,	PUNCT
dti-1420	9	13	side	side	ADJ
dti-1420	9	14	effect	effect	NOUN
dti-1420	9	15	citation	citation	NOUN
dti-1420	9	16	:	:	PUNCT
dti-1420	9	17	fragkou	fragkou	PROPN
dti-1420	9	18	et	et	PROPN
dti-1420	9	19	al	al	PROPN
dti-1420	9	20	.	.	PUNCT
dti-1420	10	1	a	a	DET
dti-1420	10	2	case	case	NOUN
dti-1420	10	3	of	of	ADP
dti-1420	10	4	organizing	organize	VERB
dti-1420	10	5	pneumonia	pneumonia	NOUN
dti-1420	10	6	(	(	PUNCT
dti-1420	10	7	op	op	NOUN
dti-1420	10	8	)	)	PUNCT
dti-1420	10	9	associated	associate	VERB
dti-1420	10	10	with	with	ADP
dti-1420	10	11	pembrolizumab	pembrolizumab	NOUN
dti-1420	10	12	.	.	PUNCT
dti-1420	10	13	drug	drug	NOUN
dti-1420	10	14	target	target	NOUN
dti-1420	10	15	insights	insight	VERB
dti-1420	10	16	2016:10	2016:10	NUM
dti-1420	10	17	9–12	9–12	NOUN
dti-1420	10	18	doi:10.4137	doi:10.4137	NOUN
dti-1420	10	19	/	/	SYM
dti-1420	10	20	dti.s31565	dti.s31565	NOUN
dti-1420	10	21	.	.	PUNCT
dti-1420	11	1	type	type	NOUN
dti-1420	11	2	:	:	PUNCT
dti-1420	11	3	case	case	NOUN
dti-1420	11	4	report	report	NOUN
dti-1420	11	5	received	receive	VERB
dti-1420	11	6	:	:	PUNCT
dti-1420	11	7	february	february	PROPN
dti-1420	11	8	5	5	NUM
dti-1420	11	9	,	,	PUNCT
dti-1420	11	10	2016	2016	NUM
dti-1420	11	11	.	.	PUNCT
dti-1420	12	1	resubmitted	resubmitte	VERB
dti-1420	12	2	:	:	PUNCT
dti-1420	12	3	april	april	PROPN
dti-1420	12	4	14	14	NUM
dti-1420	12	5	,	,	PUNCT
dti-1420	12	6	2016	2016	NUM
dti-1420	12	7	.	.	PUNCT
dti-1420	13	1	accepted	accept	VERB
dti-1420	13	2	for	for	ADP
dti-1420	13	3	publication	publication	NOUN
dti-1420	13	4	:	:	PUNCT
dti-1420	13	5	april	april	PROPN
dti-1420	13	6	18	18	NUM
dti-1420	13	7	,	,	PUNCT
dti-1420	13	8	2016	2016	NUM
dti-1420	13	9	.	.	PUNCT
dti-1420	14	1	academic	academic	ADJ
dti-1420	14	2	editor	editor	NOUN
dti-1420	14	3	:	:	PUNCT
dti-1420	14	4	anuj	anuj	PROPN
dti-1420	14	5	chauhan	chauhan	PROPN
dti-1420	14	6	,	,	PUNCT
dti-1420	14	7	editor	editor	NOUN
dti-1420	14	8	in	in	ADP
dti-1420	14	9	chief	chief	ADJ
dti-1420	14	10	peer	peer	NOUN
dti-1420	14	11	review	review	NOUN
dti-1420	14	12	:	:	PUNCT
dti-1420	14	13	three	three	NUM
dti-1420	14	14	peer	peer	NOUN
dti-1420	14	15	reviewers	reviewer	NOUN
dti-1420	14	16	contributed	contribute	VERB
dti-1420	14	17	to	to	ADP
dti-1420	14	18	the	the	DET
dti-1420	14	19	peer	peer	NOUN
dti-1420	14	20	review	review	NOUN
dti-1420	14	21	report	report	NOUN
dti-1420	14	22	.	.	PUNCT
dti-1420	15	1	reviewers	reviewer	NOUN
dti-1420	15	2	’	'	PUNCT
dti-1420	15	3	reports	report	NOUN
dti-1420	15	4	totaled	total	VERB
dti-1420	15	5	454	454	NUM
dti-1420	15	6	words	word	NOUN
dti-1420	15	7	,	,	PUNCT
dti-1420	15	8	excluding	exclude	VERB
dti-1420	15	9	any	any	DET
dti-1420	15	10	confidential	confidential	ADJ
dti-1420	15	11	comments	comment	NOUN
dti-1420	15	12	to	to	ADP
dti-1420	15	13	the	the	DET
dti-1420	15	14	academic	academic	ADJ
dti-1420	15	15	editor	editor	NOUN
dti-1420	15	16	.	.	PUNCT
dti-1420	16	1	funding	funding	NOUN
dti-1420	16	2	:	:	PUNCT
dti-1420	16	3	authors	author	NOUN
dti-1420	16	4	disclose	disclose	VERB
dti-1420	16	5	no	no	DET
dti-1420	16	6	external	external	ADJ
dti-1420	16	7	funding	funding	NOUN
dti-1420	16	8	sources	source	NOUN
dti-1420	16	9	.	.	PUNCT
dti-1420	17	1	competing	compete	VERB
dti-1420	17	2	interests	interest	NOUN
dti-1420	17	3	:	:	PUNCT
dti-1420	17	4	authors	author	NOUN
dti-1420	17	5	disclose	disclose	VERB
dti-1420	17	6	no	no	DET
dti-1420	17	7	potential	potential	ADJ
dti-1420	17	8	conflicts	conflict	NOUN
dti-1420	17	9	of	of	ADP
dti-1420	17	10	interest	interest	NOUN
dti-1420	17	11	.	.	PUNCT
dti-1420	18	1	copyright	copyright	NOUN
dti-1420	18	2	:	:	PUNCT
dti-1420	18	3	©	©	PROPN
dti-1420	18	4	the	the	DET
dti-1420	18	5	authors	author	NOUN
dti-1420	18	6	,	,	PUNCT
dti-1420	18	7	publisher	publisher	NOUN
dti-1420	18	8	and	and	CCONJ
dti-1420	18	9	licensee	licensee	NOUN
dti-1420	18	10	libertas	liberta	NOUN
dti-1420	18	11	academica	academica	PROPN
dti-1420	18	12	limited	limit	VERB
dti-1420	18	13	.	.	PUNCT
dti-1420	19	1	this	this	PRON
dti-1420	19	2	is	be	AUX
dti-1420	19	3	an	an	DET
dti-1420	19	4	open	open	ADJ
dti-1420	19	5	-	-	PUNCT
dti-1420	19	6	access	access	NOUN
dti-1420	19	7	article	article	NOUN
dti-1420	19	8	distributed	distribute	VERB
dti-1420	19	9	under	under	ADP
dti-1420	19	10	the	the	DET
dti-1420	19	11	terms	term	NOUN
dti-1420	19	12	of	of	ADP
dti-1420	19	13	the	the	DET
dti-1420	19	14	creative	creative	ADJ
dti-1420	19	15	commons	common	NOUN
dti-1420	19	16	cc	cc	NOUN
dti-1420	19	17	-	-	PUNCT
dti-1420	19	18	by	by	ADP
dti-1420	19	19	-	-	PUNCT
dti-1420	19	20	nc	nc	PROPN
dti-1420	19	21	3.0	3.0	NUM
dti-1420	19	22	license	license	NOUN
dti-1420	19	23	.	.	PUNCT
dti-1420	20	1	correspondence	correspondence	NOUN
dti-1420	20	2	:	:	PUNCT
dti-1420	21	1	akoumari@yahoo.com	akoumari@yahoo.com	X
dti-1420	21	2	paper	paper	NOUN
dti-1420	21	3	subject	subject	NOUN
dti-1420	21	4	to	to	ADP
dti-1420	21	5	independent	independent	ADJ
dti-1420	21	6	expert	expert	ADJ
dti-1420	21	7	single	single	ADJ
dti-1420	21	8	-	-	PUNCT
dti-1420	21	9	blind	blind	ADJ
dti-1420	21	10	peer	peer	NOUN
dti-1420	21	11	review	review	NOUN
dti-1420	21	12	.	.	PUNCT
dti-1420	22	1	all	all	DET
dti-1420	22	2	editorial	editorial	ADJ
dti-1420	22	3	decisions	decision	NOUN
dti-1420	22	4	made	make	VERB
dti-1420	22	5	by	by	ADP
dti-1420	22	6	independent	independent	ADJ
dti-1420	22	7	academic	academic	ADJ
dti-1420	22	8	editor	editor	NOUN
dti-1420	22	9	.	.	PUNCT
dti-1420	23	1	upon	upon	SCONJ
dti-1420	23	2	submission	submission	NOUN
dti-1420	23	3	manuscript	manuscript	NOUN
dti-1420	23	4	was	be	AUX
dti-1420	23	5	subject	subject	ADJ
dti-1420	23	6	to	to	ADP
dti-1420	23	7	anti	anti	ADJ
dti-1420	23	8	-	-	NOUN
dti-1420	23	9	plagiarism	plagiarism	ADJ
dti-1420	23	10	scanning	scanning	NOUN
dti-1420	23	11	.	.	PUNCT
dti-1420	24	1	prior	prior	ADV
dti-1420	24	2	to	to	ADP
dti-1420	24	3	publication	publication	NOUN
dti-1420	24	4	all	all	DET
dti-1420	24	5	authors	author	NOUN
dti-1420	24	6	have	have	AUX
dti-1420	24	7	given	give	VERB
dti-1420	24	8	signed	sign	VERB
dti-1420	24	9	confirmation	confirmation	NOUN
dti-1420	24	10	of	of	ADP
dti-1420	24	11	agreement	agreement	NOUN
dti-1420	24	12	to	to	ADP
dti-1420	24	13	article	article	NOUN
dti-1420	24	14	publication	publication	NOUN
dti-1420	24	15	and	and	CCONJ
dti-1420	24	16	compliance	compliance	NOUN
dti-1420	24	17	with	with	ADP
dti-1420	24	18	all	all	DET
dti-1420	24	19	applicable	applicable	ADJ
dti-1420	24	20	ethical	ethical	ADJ
dti-1420	24	21	and	and	CCONJ
dti-1420	24	22	legal	legal	ADJ
dti-1420	24	23	requirements	requirement	NOUN
dti-1420	24	24	,	,	PUNCT
dti-1420	24	25	including	include	VERB
dti-1420	24	26	the	the	DET
dti-1420	24	27	accuracy	accuracy	NOUN
dti-1420	24	28	of	of	ADP
dti-1420	24	29	author	author	NOUN
dti-1420	24	30	and	and	CCONJ
dti-1420	24	31	contributor	contributor	NOUN
dti-1420	24	32	information	information	NOUN
dti-1420	24	33	,	,	PUNCT
dti-1420	24	34	disclosure	disclosure	NOUN
dti-1420	24	35	of	of	ADP
dti-1420	24	36	competing	compete	VERB
dti-1420	24	37	interests	interest	NOUN
dti-1420	24	38	and	and	CCONJ
dti-1420	24	39	funding	funding	NOUN
dti-1420	24	40	sources	source	NOUN
dti-1420	24	41	,	,	PUNCT
dti-1420	24	42	compliance	compliance	NOUN
dti-1420	24	43	with	with	ADP
dti-1420	24	44	ethical	ethical	ADJ
dti-1420	24	45	requirements	requirement	NOUN
dti-1420	24	46	relating	relate	VERB
dti-1420	24	47	to	to	ADP
dti-1420	24	48	human	human	ADJ
dti-1420	24	49	and	and	CCONJ
dti-1420	24	50	animal	animal	NOUN
dti-1420	24	51	study	study	NOUN
dti-1420	24	52	participants	participant	NOUN
dti-1420	24	53	,	,	PUNCT
dti-1420	24	54	and	and	CCONJ
dti-1420	24	55	compliance	compliance	NOUN
dti-1420	24	56	with	with	ADP
dti-1420	24	57	any	any	DET
dti-1420	24	58	copyright	copyright	NOUN
dti-1420	24	59	requirements	requirement	NOUN
dti-1420	24	60	of	of	ADP
dti-1420	24	61	third	third	ADJ
dti-1420	24	62	parties	party	NOUN
dti-1420	24	63	.	.	PUNCT
dti-1420	25	1	this	this	DET
dti-1420	25	2	journal	journal	NOUN
dti-1420	25	3	is	be	AUX
dti-1420	25	4	a	a	DET
dti-1420	25	5	member	member	NOUN
dti-1420	25	6	of	of	ADP
dti-1420	25	7	the	the	DET
dti-1420	25	8	committee	committee	NOUN
dti-1420	25	9	on	on	ADP
dti-1420	25	10	publication	publication	NOUN
dti-1420	25	11	ethics	ethic	NOUN
dti-1420	25	12	(	(	PUNCT
dti-1420	25	13	cope	cope	PROPN
dti-1420	25	14	)	)	PUNCT
dti-1420	25	15	.	.	PUNCT
dti-1420	26	1	provenance	provenance	NOUN
dti-1420	26	2	:	:	PUNCT
dti-1420	26	3	the	the	DET
dti-1420	26	4	authors	author	NOUN
dti-1420	26	5	were	be	AUX
dti-1420	26	6	invited	invite	VERB
dti-1420	26	7	to	to	PART
dti-1420	26	8	submit	submit	VERB
dti-1420	26	9	this	this	DET
dti-1420	26	10	paper	paper	NOUN
dti-1420	26	11	.	.	PUNCT
dti-1420	27	1	published	publish	VERB
dti-1420	27	2	by	by	ADP
dti-1420	27	3	libertas	liberta	NOUN
dti-1420	27	4	academica	academica	PROPN
dti-1420	27	5	.	.	PUNCT
dti-1420	28	1	learn	learn	VERB
dti-1420	28	2	more	more	ADJ
dti-1420	28	3	about	about	ADP
dti-1420	28	4	this	this	DET
dti-1420	28	5	journal	journal	NOUN
dti-1420	28	6	.	.	PUNCT
dti-1420	29	1	introduction	introduction	NOUN
dti-1420	29	2	new	new	ADJ
dti-1420	29	3	monoclonal	monoclonal	NOUN
dti-1420	29	4	antibodies	antibody	NOUN
dti-1420	29	5	(	(	PUNCT
dti-1420	29	6	mabs	mab	NOUN
dti-1420	29	7	)	)	PUNCT
dti-1420	29	8	targeting	target	VERB
dti-1420	29	9	the	the	DET
dti-1420	29	10	immune	immune	ADJ
dti-1420	29	11	checkpoint	checkpoint	NOUN
dti-1420	29	12	blockade	blockade	NOUN
dti-1420	29	13	have	have	AUX
dti-1420	29	14	revolutionized	revolutionize	VERB
dti-1420	29	15	the	the	DET
dti-1420	29	16	treatment	treatment	NOUN
dti-1420	29	17	of	of	ADP
dti-1420	29	18	advanced	advanced	ADJ
dti-1420	29	19	melanoma	melanoma	NOUN
dti-1420	29	20	patients	patient	NOUN
dti-1420	29	21	.	.	PUNCT
dti-1420	30	1	although	although	SCONJ
dti-1420	30	2	these	these	DET
dti-1420	30	3	novel	novel	ADJ
dti-1420	30	4	mab	mab	NOUN
dti-1420	30	5	therapies	therapy	NOUN
dti-1420	30	6	can	can	AUX
dti-1420	30	7	induce	induce	VERB
dti-1420	30	8	remarkable	remarkable	ADJ
dti-1420	30	9	antitumor	antitumor	NOUN
dti-1420	30	10	-	-	PUNCT
dti-1420	30	11	specific	specific	ADJ
dti-1420	30	12	immune	immune	ADJ
dti-1420	30	13	responses	response	NOUN
dti-1420	30	14	,	,	PUNCT
dti-1420	30	15	they	they	PRON
dti-1420	30	16	have	have	VERB
dti-1420	30	17	distinct	distinct	ADJ
dti-1420	30	18	side	side	NOUN
dti-1420	30	19	effects	effect	NOUN
dti-1420	30	20	as	as	SCONJ
dti-1420	30	21	compared	compare	VERB
dti-1420	30	22	with	with	ADP
dti-1420	30	23	chemotherapy	chemotherapy	NOUN
dti-1420	30	24	,	,	PUNCT
dti-1420	30	25	including	include	VERB
dti-1420	30	26	nonspecific	nonspecific	ADJ
dti-1420	30	27	immunological	immunological	ADJ
dti-1420	30	28	activation.1	activation.1	NOUN
dti-1420	30	29	to	to	ADP
dti-1420	30	30	our	our	PRON
dti-1420	30	31	knowledge	knowledge	NOUN
dti-1420	30	32	,	,	PUNCT
dti-1420	30	33	we	we	PRON
dti-1420	30	34	report	report	VERB
dti-1420	30	35	the	the	DET
dti-1420	30	36	first	first	ADJ
dti-1420	30	37	case	case	NOUN
dti-1420	30	38	of	of	ADP
dti-1420	30	39	organizing	organize	VERB
dti-1420	30	40	pneumonia	pneumonia	NOUN
dti-1420	30	41	(	(	PUNCT
dti-1420	30	42	op	op	NOUN
dti-1420	30	43	)	)	PUNCT
dti-1420	30	44	in	in	ADP
dti-1420	30	45	a	a	DET
dti-1420	30	46	melanoma	melanoma	NOUN
dti-1420	30	47	patient	patient	NOUN
dti-1420	30	48	under	under	ADP
dti-1420	30	49	immunotherapy	immunotherapy	NOUN
dti-1420	30	50	with	with	ADP
dti-1420	30	51	pembrolizumab	pembrolizumab	NOUN
dti-1420	30	52	,	,	PUNCT
dti-1420	30	53	a	a	DET
dti-1420	30	54	pd-1	pd-1	ADV
dti-1420	30	55	targeting	target	VERB
dti-1420	30	56	mab	mab	NOUN
dti-1420	30	57	.	.	PUNCT
dti-1420	31	1	the	the	DET
dti-1420	31	2	patient	patient	NOUN
dti-1420	31	3	’s	’s	ADV
dti-1420	31	4	next	next	ADV
dti-1420	31	5	of	of	ADP
dti-1420	31	6	kin	kin	PROPN
dti-1420	31	7	has	have	AUX
dti-1420	31	8	given	give	VERB
dti-1420	31	9	consent	consent	NOUN
dti-1420	31	10	for	for	ADP
dti-1420	31	11	publication	publication	NOUN
dti-1420	31	12	of	of	ADP
dti-1420	31	13	this	this	DET
dti-1420	31	14	report	report	NOUN
dti-1420	31	15	.	.	PUNCT
dti-1420	32	1	case	case	NOUN
dti-1420	32	2	presentation	presentation	NOUN
dti-1420	32	3	a	a	DET
dti-1420	32	4	64	64	NUM
dti-1420	32	5	-	-	PUNCT
dti-1420	32	6	year	year	NOUN
dti-1420	32	7	-	-	PUNCT
dti-1420	32	8	old	old	ADJ
dti-1420	32	9	woman	woman	NOUN
dti-1420	32	10	presented	present	VERB
dti-1420	32	11	to	to	ADP
dti-1420	32	12	our	our	PRON
dti-1420	32	13	emergency	emergency	NOUN
dti-1420	32	14	department	department	NOUN
dti-1420	32	15	with	with	ADP
dti-1420	32	16	a	a	DET
dti-1420	32	17	10	10	NUM
dti-1420	32	18	-	-	PUNCT
dti-1420	32	19	day	day	NOUN
dti-1420	32	20	history	history	NOUN
dti-1420	32	21	of	of	ADP
dti-1420	32	22	progressive	progressive	ADJ
dti-1420	32	23	dyspnea	dyspnea	NOUN
dti-1420	32	24	and	and	CCONJ
dti-1420	32	25	dry	dry	ADJ
dti-1420	32	26	cough	cough	NOUN
dti-1420	32	27	nonresolving	nonresolve	VERB
dti-1420	32	28	after	after	ADP
dti-1420	32	29	a	a	DET
dti-1420	32	30	9	9	NUM
dti-1420	32	31	-	-	PUNCT
dti-1420	32	32	day	day	NOUN
dti-1420	32	33	course	course	NOUN
dti-1420	32	34	of	of	ADP
dti-1420	32	35	oral	oral	ADJ
dti-1420	32	36	antibiotics	antibiotic	NOUN
dti-1420	32	37	(	(	PUNCT
dti-1420	32	38	levofloxacin	levofloxacin	NOUN
dti-1420	32	39	750	750	NUM
dti-1420	32	40	 	 	SPACE
dti-1420	32	41	mg	mg	PROPN
dti-1420	32	42	daily	daily	ADV
dti-1420	32	43	)	)	PUNCT
dti-1420	32	44	.	.	PUNCT
dti-1420	33	1	she	she	PRON
dti-1420	33	2	had	have	AUX
dti-1420	33	3	been	be	AUX
dti-1420	33	4	diagnosed	diagnose	VERB
dti-1420	33	5	with	with	ADP
dti-1420	33	6	a	a	DET
dti-1420	33	7	c	c	NOUN
dti-1420	33	8	-	-	PUNCT
dti-1420	33	9	kit	kit	NOUN
dti-1420	33	10	/	/	SYM
dti-1420	33	11	braf	braf	NOUN
dti-1420	33	12	wild	wild	ADJ
dti-1420	33	13	-	-	PUNCT
dti-1420	33	14	type	type	NOUN
dti-1420	33	15	,	,	PUNCT
dti-1420	33	16	stage	stage	NOUN
dti-1420	33	17	iv	iv	NUM
dti-1420	33	18	mucosal	mucosal	ADJ
dti-1420	33	19	melanoma	melanoma	NOUN
dti-1420	33	20	of	of	ADP
dti-1420	33	21	the	the	DET
dti-1420	33	22	nasal	nasal	ADJ
dti-1420	33	23	cavity	cavity	NOUN
dti-1420	33	24	with	with	ADP
dti-1420	33	25	involvement	involvement	NOUN
dti-1420	33	26	of	of	ADP
dti-1420	33	27	cervical	cervical	ADJ
dti-1420	33	28	and	and	CCONJ
dti-1420	33	29	mediastinal	mediastinal	ADJ
dti-1420	33	30	lymph	lymph	NOUN
dti-1420	33	31	nodes	node	NOUN
dti-1420	33	32	and	and	CCONJ
dti-1420	33	33	metastases	metastasis	NOUN
dti-1420	33	34	to	to	ADP
dti-1420	33	35	the	the	DET
dti-1420	33	36	liver	liver	NOUN
dti-1420	33	37	,	,	PUNCT
dti-1420	33	38	brain	brain	NOUN
dti-1420	33	39	,	,	PUNCT
dti-1420	33	40	and	and	CCONJ
dti-1420	33	41	bones	bone	NOUN
dti-1420	33	42	nine	nine	NUM
dti-1420	33	43	months	month	NOUN
dti-1420	33	44	earlier	early	ADV
dti-1420	33	45	.	.	PUNCT
dti-1420	34	1	initial	initial	ADJ
dti-1420	34	2	treatment	treatment	NOUN
dti-1420	34	3	included	include	VERB
dti-1420	34	4	two	two	NUM
dti-1420	34	5	cycles	cycle	NOUN
dti-1420	34	6	of	of	ADP
dti-1420	34	7	dacarbazine	dacarbazine	NOUN
dti-1420	34	8	1000	1000	NUM
dti-1420	34	9	 	 	SPACE
dti-1420	34	10	mg	mg	PROPN
dti-1420	34	11	/	/	SYM
dti-1420	34	12	m2	m2	PROPN
dti-1420	34	13	and	and	CCONJ
dti-1420	34	14	zoledronic	zoledronic	ADJ
dti-1420	34	15	acid	acid	NOUN
dti-1420	34	16	4	4	NUM
dti-1420	34	17	 	 	SPACE
dti-1420	34	18	mg	mg	NOUN
dti-1420	34	19	every	every	DET
dti-1420	34	20	three	three	NUM
dti-1420	34	21	weeks	week	NOUN
dti-1420	34	22	.	.	PUNCT
dti-1420	35	1	one	one	NUM
dti-1420	35	2	month	month	NOUN
dti-1420	35	3	later	later	ADV
dti-1420	35	4	,	,	PUNCT
dti-1420	35	5	the	the	DET
dti-1420	35	6	patient	patient	NOUN
dti-1420	35	7	experienced	experience	VERB
dti-1420	35	8	disease	disease	NOUN
dti-1420	35	9	progression	progression	NOUN
dti-1420	35	10	and	and	CCONJ
dti-1420	35	11	was	be	AUX
dti-1420	35	12	treated	treat	VERB
dti-1420	35	13	with	with	ADP
dti-1420	35	14	four	four	NUM
dti-1420	35	15	cycles	cycle	NOUN
dti-1420	35	16	of	of	ADP
dti-1420	35	17	ipilimumab	ipilimumab	ADJ
dti-1420	35	18	immunotherapy	immunotherapy	NOUN
dti-1420	35	19	3	3	NUM
dti-1420	35	20	 	 	SPACE
dti-1420	35	21	mg	mg	PROPN
dti-1420	35	22	/	/	SYM
dti-1420	35	23	kg	kg	PROPN
dti-1420	35	24	and	and	CCONJ
dti-1420	35	25	zoledronic	zoledronic	ADJ
dti-1420	35	26	acid	acid	NOUN
dti-1420	35	27	4	4	NUM
dti-1420	35	28	 	 	SPACE
dti-1420	35	29	mg	mg	PROPN
dti-1420	35	30	q3	q3	PROPN
dti-1420	35	31	weeks	week	NOUN
dti-1420	35	32	intravenously	intravenously	ADV
dti-1420	35	33	(	(	PUNCT
dti-1420	35	34	iv	iv	X
dti-1420	35	35	)	)	PUNCT
dti-1420	35	36	.	.	PUNCT
dti-1420	36	1	three	three	NUM
dti-1420	36	2	months	month	NOUN
dti-1420	36	3	later	later	ADV
dti-1420	36	4	,	,	PUNCT
dti-1420	36	5	the	the	DET
dti-1420	36	6	disease	disease	NOUN
dti-1420	36	7	advanced	advance	VERB
dti-1420	36	8	further	far	ADV
dti-1420	36	9	,	,	PUNCT
dti-1420	36	10	and	and	CCONJ
dti-1420	36	11	a	a	DET
dti-1420	36	12	second	second	ADJ
dti-1420	36	13	-	-	PUNCT
dti-1420	36	14	line	line	NOUN
dti-1420	36	15	immunotherapeutic	immunotherapeutic	ADJ
dti-1420	36	16	agent	agent	NOUN
dti-1420	36	17	with	with	ADP
dti-1420	36	18	pembrolizumab	pembrolizumab	NOUN
dti-1420	36	19	was	be	AUX
dti-1420	36	20	initiated	initiate	VERB
dti-1420	36	21	.	.	PUNCT
dti-1420	37	1	thirteen	thirteen	NUM
dti-1420	37	2	days	day	NOUN
dti-1420	37	3	prior	prior	ADV
dti-1420	37	4	to	to	ADP
dti-1420	37	5	her	her	PRON
dti-1420	37	6	admission	admission	NOUN
dti-1420	37	7	,	,	PUNCT
dti-1420	37	8	she	she	PRON
dti-1420	37	9	had	have	AUX
dti-1420	37	10	received	receive	VERB
dti-1420	37	11	her	her	PRON
dti-1420	37	12	fourth	fourth	ADJ
dti-1420	37	13	cycle	cycle	NOUN
dti-1420	37	14	of	of	ADP
dti-1420	37	15	immunotherapy	immunotherapy	NOUN
dti-1420	37	16	with	with	ADP
dti-1420	37	17	pembrolizumab	pembrolizumab	NOUN
dti-1420	37	18	.	.	PUNCT
dti-1420	38	1	her	her	PRON
dti-1420	38	2	pretherapeutic	pretherapeutic	ADJ
dti-1420	38	3	thoracic	thoracic	NOUN
dti-1420	38	4	ct	ct	PROPN
dti-1420	38	5	scan	scan	PROPN
dti-1420	38	6	was	be	AUX
dti-1420	38	7	normal	normal	ADJ
dti-1420	38	8	.	.	PUNCT
dti-1420	39	1	on	on	ADP
dti-1420	39	2	examination	examination	NOUN
dti-1420	39	3	,	,	PUNCT
dti-1420	39	4	she	she	PRON
dti-1420	39	5	was	be	AUX
dti-1420	39	6	pale	pale	ADJ
dti-1420	39	7	and	and	CCONJ
dti-1420	39	8	tachypneic	tachypneic	NOUN
dti-1420	39	9	.	.	PUNCT
dti-1420	40	1	the	the	DET
dti-1420	40	2	chest	chest	NOUN
dti-1420	40	3	auscultation	auscultation	NOUN
dti-1420	40	4	revealed	reveal	VERB
dti-1420	40	5	diffuse	diffuse	ADJ
dti-1420	40	6	bilateral	bilateral	ADJ
dti-1420	40	7	coarse	coarse	ADJ
dti-1420	40	8	crackles	crackle	NOUN
dti-1420	40	9	and	and	CCONJ
dti-1420	40	10	areas	area	NOUN
dti-1420	40	11	of	of	ADP
dti-1420	40	12	bronchial	bronchial	ADJ
dti-1420	40	13	breathing	breathing	NOUN
dti-1420	40	14	mainly	mainly	ADV
dti-1420	40	15	in	in	ADP
dti-1420	40	16	the	the	DET
dti-1420	40	17	right	right	ADJ
dti-1420	40	18	middle	middle	ADJ
dti-1420	40	19	lobe	lobe	PROPN
dti-1420	40	20	.	.	PUNCT
dti-1420	41	1	she	she	PRON
dti-1420	41	2	was	be	AUX
dti-1420	41	3	afebrile	afebrile	ADJ
dti-1420	41	4	,	,	PUNCT
dti-1420	41	5	but	but	CCONJ
dti-1420	41	6	her	her	PRON
dti-1420	41	7	oxygen	oxygen	NOUN
dti-1420	41	8	saturation	saturation	NOUN
dti-1420	41	9	on	on	ADP
dti-1420	41	10	room	room	NOUN
dti-1420	41	11	air	air	NOUN
dti-1420	41	12	was	be	AUX
dti-1420	41	13	75	75	NUM
dti-1420	41	14	%	%	NOUN
dti-1420	41	15	.	.	PUNCT
dti-1420	42	1	her	her	PRON
dti-1420	42	2	blood	blood	NOUN
dti-1420	42	3	tests	test	NOUN
dti-1420	42	4	were	be	AUX
dti-1420	42	5	normal	normal	ADJ
dti-1420	42	6	except	except	SCONJ
dti-1420	42	7	an	an	DET
dti-1420	42	8	erythrocyte	erythrocyte	NOUN
dti-1420	42	9	sedimentation	sedimentation	NOUN
dti-1420	42	10	rate	rate	NOUN
dti-1420	42	11	of	of	ADP
dti-1420	42	12	200	200	NUM
dti-1420	42	13	 	 	SPACE
dti-1420	42	14	mm	mm	NUM
dti-1420	42	15	/	/	SYM
dti-1420	42	16	hour	hour	NOUN
dti-1420	42	17	,	,	PUNCT
dti-1420	42	18	a	a	DET
dti-1420	42	19	white	white	ADJ
dti-1420	42	20	blood	blood	NOUN
dti-1420	42	21	count	count	NOUN
dti-1420	42	22	of	of	ADP
dti-1420	42	23	10,970	10,970	NUM
dti-1420	42	24	  	  	SPACE
dti-1420	42	25	cells	cell	NOUN
dti-1420	42	26	/	/	SYM
dti-1420	42	27	μl	μl	PROPN
dti-1420	42	28	(	(	PUNCT
dti-1420	42	29	differential	differential	NOUN
dti-1420	42	30	:	:	PUNCT
dti-1420	42	31	83.6	83.6	NUM
dti-1420	42	32	%	%	NOUN
dti-1420	42	33	neutrophils	neutrophil	NOUN
dti-1420	42	34	,	,	PUNCT
dti-1420	42	35	9.7	9.7	NUM
dti-1420	42	36	%	%	NOUN
dti-1420	42	37	lymphocytes	lymphocyte	NOUN
dti-1420	42	38	,	,	PUNCT
dti-1420	42	39	and	and	CCONJ
dti-1420	42	40	6.7	6.7	NUM
dti-1420	42	41	%	%	NOUN
dti-1420	42	42	monocytes	monocyte	NOUN
dti-1420	42	43	)	)	PUNCT
dti-1420	42	44	,	,	PUNCT
dti-1420	42	45	and	and	CCONJ
dti-1420	42	46	a	a	DET
dti-1420	42	47	c	c	NOUN
dti-1420	42	48	-	-	ADJ
dti-1420	42	49	reactive	reactive	ADJ
dti-1420	42	50	protein	protein	NOUN
dti-1420	42	51	of	of	ADP
dti-1420	42	52	173	173	NUM
dti-1420	42	53	  	  	SPACE
dti-1420	42	54	mg	mg	PROPN
dti-1420	42	55	/	/	SYM
dti-1420	42	56	l	l	NOUN
dti-1420	42	57	(	(	PUNCT
dti-1420	42	58	normal	normal	ADJ
dti-1420	42	59	value	value	NOUN
dti-1420	42	60	:	:	PUNCT
dti-1420	42	61	0–6	0–6	NOUN
dti-1420	42	62	  	  	SPACE
dti-1420	42	63	mg	mg	PROPN
dti-1420	42	64	/	/	SYM
dti-1420	42	65	l	l	NOUN
dti-1420	42	66	)	)	PUNCT
dti-1420	42	67	.	.	PUNCT
dti-1420	43	1	a	a	DET
dti-1420	43	2	chest	chest	NOUN
dti-1420	43	3	radiography	radiography	NOUN
dti-1420	43	4	demonstrated	demonstrate	VERB
dti-1420	43	5	patchy	patchy	ADJ
dti-1420	43	6	alveolar	alveolar	ADJ
dti-1420	43	7	infiltrates	infiltrate	NOUN
dti-1420	43	8	mainly	mainly	ADV
dti-1420	43	9	on	on	ADP
dti-1420	43	10	the	the	DET
dti-1420	43	11	right	right	ADJ
dti-1420	43	12	upper	upper	NOUN
dti-1420	43	13	,	,	PUNCT
dti-1420	43	14	the	the	DET
dti-1420	43	15	right	right	ADJ
dti-1420	43	16	middle	middle	NOUN
dti-1420	43	17	,	,	PUNCT
dti-1420	43	18	and	and	CCONJ
dti-1420	43	19	the	the	DET
dti-1420	43	20	left	left	ADJ
dti-1420	43	21	upper	upper	ADJ
dti-1420	43	22	lobe	lobe	NOUN
dti-1420	43	23	.	.	PUNCT
dti-1420	44	1	an	an	DET
dti-1420	44	2	initial	initial	ADJ
dti-1420	44	3	diagnosis	diagnosis	NOUN
dti-1420	44	4	of	of	ADP
dti-1420	44	5	a	a	DET
dti-1420	44	6	lower	low	ADJ
dti-1420	44	7	respiratory	respiratory	ADJ
dti-1420	44	8	tract	tract	NOUN
dti-1420	44	9	infection	infection	NOUN
dti-1420	44	10	was	be	AUX
dti-1420	44	11	made	make	VERB
dti-1420	44	12	,	,	PUNCT
dti-1420	44	13	and	and	CCONJ
dti-1420	44	14	antibiotics	antibiotic	NOUN
dti-1420	44	15	were	be	AUX
dti-1420	44	16	commenced	commence	VERB
dti-1420	44	17	,	,	PUNCT
dti-1420	44	18	including	include	VERB
dti-1420	44	19	ceftriaxone	ceftriaxone	PROPN
dti-1420	44	20	2	2	NUM
dti-1420	44	21	  	  	SPACE
dti-1420	44	22	g	g	NOUN
dti-1420	44	23	/	/	SYM
dti-1420	44	24	day	day	NOUN
dti-1420	44	25	iv	iv	NUM
dti-1420	44	26	and	and	CCONJ
dti-1420	44	27	azithromycin	azithromycin	VERB
dti-1420	44	28	500	500	NUM
dti-1420	44	29	  	  	SPACE
dti-1420	44	30	mg	mg	PROPN
dti-1420	44	31	/	/	SYM
dti-1420	44	32	day	day	NOUN
dti-1420	44	33	orally	orally	ADV
dti-1420	44	34	.	.	PUNCT
dti-1420	45	1	after	after	ADP
dti-1420	45	2	three	three	NUM
dti-1420	45	3	days	day	NOUN
dti-1420	45	4	of	of	ADP
dti-1420	45	5	treatment	treatment	NOUN
dti-1420	45	6	,	,	PUNCT
dti-1420	45	7	there	there	PRON
dti-1420	45	8	was	be	VERB
dti-1420	45	9	no	no	DET
dti-1420	45	10	improvement	improvement	NOUN
dti-1420	45	11	of	of	ADP
dti-1420	45	12	signs	sign	NOUN
dti-1420	45	13	or	or	CCONJ
dti-1420	45	14	symptoms	symptom	NOUN
dti-1420	45	15	.	.	PUNCT
dti-1420	46	1	subsequently	subsequently	ADV
dti-1420	46	2	,	,	PUNCT
dti-1420	46	3	the	the	DET
dti-1420	46	4	patient	patient	NOUN
dti-1420	46	5	underwent	undergo	VERB
dti-1420	46	6	a	a	DET
dti-1420	46	7	high	high	ADJ
dti-1420	46	8	-	-	PUNCT
dti-1420	46	9	resolution	resolution	NOUN
dti-1420	46	10	computed	compute	VERB
dti-1420	46	11	tomography	tomography	NOUN
dti-1420	46	12	(	(	PUNCT
dti-1420	46	13	hrct	hrct	PROPN
dti-1420	46	14	)	)	PUNCT
dti-1420	46	15	of	of	ADP
dti-1420	46	16	the	the	DET
dti-1420	46	17	chest	chest	NOUN
dti-1420	46	18	and	and	CCONJ
dti-1420	46	19	fiberoptic	fiberoptic	ADJ
dti-1420	46	20	bronchoscopy	bronchoscopy	NOUN
dti-1420	46	21	with	with	ADP
dti-1420	46	22	bronchoalveolar	bronchoalveolar	ADJ
dti-1420	46	23	lavage	lavage	NOUN
dti-1420	46	24	(	(	PUNCT
dti-1420	46	25	bal	bal	ADJ
dti-1420	46	26	)	)	PUNCT
dti-1420	46	27	.	.	PUNCT
dti-1420	47	1	samples	sample	NOUN
dti-1420	47	2	were	be	AUX
dti-1420	47	3	submitted	submit	VERB
dti-1420	47	4	for	for	ADP
dti-1420	47	5	staining	stain	VERB
dti-1420	47	6	and	and	CCONJ
dti-1420	47	7	culture	culture	NOUN
dti-1420	47	8	for	for	ADP
dti-1420	47	9	journal	journal	NOUN
dti-1420	47	10	name	name	NOUN
dti-1420	47	11	:	:	PUNCT
dti-1420	47	12	drug	drug	NOUN
dti-1420	47	13	target	target	NOUN
dti-1420	47	14	insights	insight	NOUN
dti-1420	47	15	journal	journal	NOUN
dti-1420	47	16	type	type	NOUN
dti-1420	47	17	:	:	PUNCT
dti-1420	47	18	case	case	NOUN
dti-1420	47	19	report	report	NOUN
dti-1420	47	20	year	year	NOUN
dti-1420	47	21	:	:	PUNCT
dti-1420	47	22	2016	2016	NUM
dti-1420	47	23	volume	volume	NOUN
dti-1420	47	24	:	:	PUNCT
dti-1420	47	25	10	10	NUM
dti-1420	47	26	running	run	VERB
dti-1420	47	27	head	head	NOUN
dti-1420	47	28	verso	verso	ADJ
dti-1420	47	29	:	:	PUNCT
dti-1420	47	30	fragkou	fragkou	PROPN
dti-1420	47	31	et	et	NOUN
dti-1420	47	32	al	al	PROPN
dti-1420	47	33	running	run	VERB
dti-1420	47	34	head	head	NOUN
dti-1420	47	35	recto	recto	ADJ
dti-1420	47	36	:	:	PUNCT
dti-1420	47	37	op	op	NOUN
dti-1420	47	38	in	in	ADP
dti-1420	47	39	pembrolizumab	pembrolizumab	NOUN
dti-1420	47	40	http://www.la-press.com/drug-target-insights-journal-j23	http://www.la-press.com/drug-target-insights-journal-j23	PROPN
dti-1420	47	41	http://www.la-press.com	http://www.la-press.com	X
dti-1420	47	42	http://dx.doi.org/10.4137/dti.s31565	http://dx.doi.org/10.4137/dti.s31565	PROPN
dti-1420	47	43	http://creativecommons.org/licenses/by-nc/3.0/	http://creativecommons.org/licenses/by-nc/3.0/	NOUN
dti-1420	47	44	http://creativecommons.org/licenses/by-nc/3.0/	http://creativecommons.org/licenses/by-nc/3.0/	NOUN
dti-1420	47	45	mailto:akoumari@yahoo.com	mailto:akoumari@yahoo.com	X
dti-1420	47	46	http://www.la-press.com	http://www.la-press.com	X
dti-1420	47	47	http://www.la-press.com/drug-target-insights-journal-j23	http://www.la-press.com/drug-target-insights-journal-j23	AUX
dti-1420	47	48	fragkou	fragkou	PROPN
dti-1420	47	49	et	et	NOUN
dti-1420	47	50	al	al	PROPN
dti-1420	47	51	10	10	NUM
dti-1420	47	52	drug	drug	NOUN
dti-1420	47	53	target	target	NOUN
dti-1420	47	54	insights	insight	VERB
dti-1420	47	55	2016:10	2016:10	NUM
dti-1420	47	56	bacteria	bacteria	NOUN
dti-1420	47	57	,	,	PUNCT
dti-1420	47	58	fungi	fungus	NOUN
dti-1420	47	59	,	,	PUNCT
dti-1420	47	60	mycobacteria	mycobacterium	NOUN
dti-1420	47	61	,	,	PUNCT
dti-1420	47	62	and	and	CCONJ
dti-1420	47	63	nocardia	nocardia	PROPN
dti-1420	47	64	,	,	PUNCT
dti-1420	47	65	special	special	ADJ
dti-1420	47	66	staining	staining	NOUN
dti-1420	47	67	for	for	ADP
dti-1420	47	68	pneumocystis	pneumocystis	ADJ
dti-1420	47	69	jirovecii	jirovecii	NOUN
dti-1420	47	70	,	,	PUNCT
dti-1420	47	71	cytology	cytology	NOUN
dti-1420	47	72	,	,	PUNCT
dti-1420	47	73	immunophenotyping	immunophenotyping	NOUN
dti-1420	47	74	,	,	PUNCT
dti-1420	47	75	and	and	CCONJ
dti-1420	47	76	molecular	molecular	ADJ
dti-1420	47	77	testing	testing	NOUN
dti-1420	47	78	for	for	ADP
dti-1420	47	79	viral	viral	ADJ
dti-1420	47	80	infection	infection	NOUN
dti-1420	47	81	.	.	PUNCT
dti-1420	48	1	the	the	DET
dti-1420	48	2	hrct	hrct	NOUN
dti-1420	48	3	demonstrated	demonstrate	VERB
dti-1420	48	4	patchy	patchy	ADJ
dti-1420	48	5	consolidation	consolidation	NOUN
dti-1420	48	6	with	with	ADP
dti-1420	48	7	a	a	DET
dti-1420	48	8	predominantly	predominantly	ADV
dti-1420	48	9	subpleural	subpleural	ADJ
dti-1420	48	10	and	and	CCONJ
dti-1420	48	11	peribronchial	peribronchial	ADJ
dti-1420	48	12	distribution	distribution	NOUN
dti-1420	48	13	,	,	PUNCT
dti-1420	48	14	small	small	ADJ
dti-1420	48	15	ill	ill	ADV
dti-1420	48	16	-	-	PUNCT
dti-1420	48	17	defined	define	VERB
dti-1420	48	18	peribronchiolar	peribronchiolar	ADJ
dti-1420	48	19	nodules	nodule	NOUN
dti-1420	48	20	,	,	PUNCT
dti-1420	48	21	tree	tree	NOUN
dti-1420	48	22	-	-	PUNCT
dti-1420	48	23	in	in	ADP
dti-1420	48	24	-	-	PUNCT
dti-1420	48	25	bud	bud	NOUN
dti-1420	48	26	sign	sign	NOUN
dti-1420	48	27	,	,	PUNCT
dti-1420	48	28	and	and	CCONJ
dti-1420	48	29	reverse	reverse	VERB
dti-1420	48	30	halo	halo	NOUN
dti-1420	48	31	sign	sign	NOUN
dti-1420	48	32	,	,	PUNCT
dti-1420	48	33	involving	involve	VERB
dti-1420	48	34	all	all	DET
dti-1420	48	35	lobes	lobe	NOUN
dti-1420	48	36	mainly	mainly	ADV
dti-1420	48	37	the	the	DET
dti-1420	48	38	lower	low	ADJ
dti-1420	48	39	ones	one	NOUN
dti-1420	48	40	(	(	PUNCT
dti-1420	48	41	fig	fig	NOUN
dti-1420	48	42	.	.	PUNCT
dti-1420	49	1	1	1	NUM
dti-1420	49	2	)	)	PUNCT
dti-1420	49	3	.	.	PUNCT
dti-1420	50	1	there	there	PRON
dti-1420	50	2	was	be	VERB
dti-1420	50	3	no	no	DET
dti-1420	50	4	lymph	lymph	NOUN
dti-1420	50	5	nodal	nodal	NOUN
dti-1420	50	6	enlargement	enlargement	NOUN
dti-1420	50	7	or	or	CCONJ
dti-1420	50	8	pleural	pleural	ADJ
dti-1420	50	9	effusion	effusion	NOUN
dti-1420	50	10	.	.	PUNCT
dti-1420	51	1	cytology	cytology	NOUN
dti-1420	51	2	,	,	PUNCT
dti-1420	51	3	microbiology	microbiology	NOUN
dti-1420	51	4	,	,	PUNCT
dti-1420	51	5	and	and	CCONJ
dti-1420	51	6	molecular	molecular	ADJ
dti-1420	51	7	testing	testing	NOUN
dti-1420	51	8	were	be	AUX
dti-1420	51	9	negative	negative	ADJ
dti-1420	51	10	for	for	ADP
dti-1420	51	11	malignant	malignant	ADJ
dti-1420	51	12	or	or	CCONJ
dti-1420	51	13	infectious	infectious	ADJ
dti-1420	51	14	diseases	disease	NOUN
dti-1420	51	15	.	.	PUNCT
dti-1420	52	1	the	the	DET
dti-1420	52	2	immunophenotyping	immunophenotyping	NOUN
dti-1420	52	3	of	of	ADP
dti-1420	52	4	the	the	DET
dti-1420	52	5	bal	bal	PROPN
dti-1420	52	6	lymphocytes	lymphocyte	NOUN
dti-1420	52	7	by	by	ADP
dti-1420	52	8	flow	flow	NOUN
dti-1420	52	9	cytometry	cytometry	NOUN
dti-1420	52	10	revealed	reveal	VERB
dti-1420	52	11	macrophage	macrophage	ADJ
dti-1420	52	12	and	and	CCONJ
dti-1420	52	13	monocyte	monocyte	NOUN
dti-1420	52	14	predominance	predominance	NOUN
dti-1420	52	15	(	(	PUNCT
dti-1420	52	16	60.7	60.7	NUM
dti-1420	52	17	%	%	NOUN
dti-1420	52	18	)	)	PUNCT
dti-1420	52	19	with	with	ADP
dti-1420	52	20	a	a	DET
dti-1420	52	21	lymphocyte	lymphocyte	ADJ
dti-1420	52	22	count	count	NOUN
dti-1420	52	23	of	of	ADP
dti-1420	52	24	28.7	28.7	NUM
dti-1420	52	25	%	%	NOUN
dti-1420	52	26	and	and	CCONJ
dti-1420	52	27	a	a	DET
dti-1420	52	28	cd4+/cd8	cd4+/cd8	NOUN
dti-1420	52	29	+	+	NUM
dti-1420	52	30	index	index	NOUN
dti-1420	52	31	of	of	ADP
dti-1420	52	32	0.4	0.4	NUM
dti-1420	52	33	.	.	PUNCT
dti-1420	53	1	based	base	VERB
dti-1420	53	2	on	on	ADP
dti-1420	53	3	the	the	DET
dti-1420	53	4	imaging	imaging	NOUN
dti-1420	53	5	and	and	CCONJ
dti-1420	53	6	clinical	clinical	ADJ
dti-1420	53	7	and	and	CCONJ
dti-1420	53	8	bal	bal	PROPN
dti-1420	53	9	findings	finding	NOUN
dti-1420	53	10	that	that	PRON
dti-1420	53	11	were	be	AUX
dti-1420	53	12	consistent	consistent	ADJ
dti-1420	53	13	with	with	ADP
dti-1420	53	14	op	op	NOUN
dti-1420	53	15	,	,	PUNCT
dti-1420	53	16	therapy	therapy	NOUN
dti-1420	53	17	with	with	ADP
dti-1420	53	18	corticosteroids	corticosteroid	NOUN
dti-1420	53	19	(	(	PUNCT
dti-1420	53	20	prednisolone	prednisolone	PROPN
dti-1420	53	21	50	50	NUM
dti-1420	53	22	 	 	SPACE
dti-1420	53	23	mg	mg	PROPN
dti-1420	53	24	/	/	SYM
dti-1420	53	25	day	day	NOUN
dti-1420	53	26	iv	iv	NUM
dti-1420	53	27	)	)	PUNCT
dti-1420	53	28	was	be	AUX
dti-1420	53	29	initiated	initiate	VERB
dti-1420	53	30	that	that	PRON
dti-1420	53	31	resulted	result	VERB
dti-1420	53	32	into	into	ADP
dti-1420	53	33	rapid	rapid	ADJ
dti-1420	53	34	clinical	clinical	ADJ
dti-1420	53	35	and	and	CCONJ
dti-1420	53	36	radiographic	radiographic	ADJ
dti-1420	53	37	improvement	improvement	NOUN
dti-1420	53	38	of	of	ADP
dti-1420	53	39	the	the	DET
dti-1420	53	40	patient	patient	NOUN
dti-1420	53	41	.	.	PUNCT
dti-1420	54	1	her	her	PRON
dti-1420	54	2	c	c	ADJ
dti-1420	54	3	-	-	ADJ
dti-1420	54	4	reactive	reactive	ADJ
dti-1420	54	5	protein	protein	NOUN
dti-1420	54	6	declined	decline	VERB
dti-1420	54	7	to	to	ADP
dti-1420	54	8	20	20	NUM
dti-1420	54	9	 	 	SPACE
dti-1420	54	10	mg	mg	PROPN
dti-1420	54	11	/	/	SYM
dti-1420	54	12	l	l	NOUN
dti-1420	54	13	within	within	ADP
dti-1420	54	14	two	two	NUM
dti-1420	54	15	days	day	NOUN
dti-1420	54	16	of	of	ADP
dti-1420	54	17	steroid	steroid	NOUN
dti-1420	54	18	treatment	treatment	NOUN
dti-1420	54	19	.	.	PUNCT
dti-1420	55	1	the	the	DET
dti-1420	55	2	treating	treat	VERB
dti-1420	55	3	physician	physician	NOUN
dti-1420	55	4	assessed	assess	VERB
dti-1420	55	5	that	that	SCONJ
dti-1420	55	6	op	op	NOUN
dti-1420	55	7	represented	represent	VERB
dti-1420	55	8	a	a	DET
dti-1420	55	9	grade	grade	NOUN
dti-1420	55	10	3	3	NUM
dti-1420	55	11	adverse	adverse	ADJ
dti-1420	55	12	event,2	event,2	NOUN
dti-1420	55	13	most	most	ADV
dti-1420	55	14	probably	probably	ADV
dti-1420	55	15	related	relate	VERB
dti-1420	55	16	to	to	ADP
dti-1420	55	17	treatment	treatment	NOUN
dti-1420	55	18	with	with	ADP
dti-1420	55	19	pembrolizumab	pembrolizumab	NOUN
dti-1420	55	20	,	,	PUNCT
dti-1420	55	21	which	which	PRON
dti-1420	55	22	was	be	AUX
dti-1420	55	23	discontinued	discontinue	VERB
dti-1420	55	24	.	.	PUNCT
dti-1420	56	1	three	three	NUM
dti-1420	56	2	months	month	NOUN
dti-1420	56	3	later	later	ADV
dti-1420	56	4	,	,	PUNCT
dti-1420	56	5	the	the	DET
dti-1420	56	6	patient	patient	NOUN
dti-1420	56	7	died	die	VERB
dti-1420	56	8	of	of	ADP
dti-1420	56	9	advanced	advanced	ADJ
dti-1420	56	10	metastatic	metastatic	ADJ
dti-1420	56	11	disease	disease	NOUN
dti-1420	56	12	in	in	ADP
dti-1420	56	13	the	the	DET
dti-1420	56	14	brain	brain	NOUN
dti-1420	56	15	.	.	PUNCT
dti-1420	57	1	discussion	discussion	NOUN
dti-1420	57	2	advanced	advanced	ADJ
dti-1420	57	3	melanoma	melanoma	NOUN
dti-1420	57	4	has	have	AUX
dti-1420	57	5	been	be	AUX
dti-1420	57	6	a	a	DET
dti-1420	57	7	challenge	challenge	NOUN
dti-1420	57	8	in	in	ADP
dti-1420	57	9	oncology	oncology	NOUN
dti-1420	57	10	as	as	SCONJ
dti-1420	57	11	the	the	DET
dti-1420	57	12	five	five	NUM
dti-1420	57	13	-	-	PUNCT
dti-1420	57	14	year	year	NOUN
dti-1420	57	15	survival	survival	NOUN
dti-1420	57	16	rates	rate	NOUN
dti-1420	57	17	were	be	AUX
dti-1420	57	18	immensely	immensely	ADV
dti-1420	57	19	low	low	ADJ
dti-1420	57	20	with	with	ADP
dti-1420	57	21	standard	standard	ADJ
dti-1420	57	22	chemotherapy.3	chemotherapy.3	PROPN
dti-1420	57	23	newer	new	ADJ
dti-1420	57	24	mab	mab	NOUN
dti-1420	57	25	therapies	therapy	NOUN
dti-1420	57	26	targeting	target	VERB
dti-1420	57	27	the	the	DET
dti-1420	57	28	immune	immune	ADJ
dti-1420	57	29	checkpoint	checkpoint	NOUN
dti-1420	57	30	,	,	PUNCT
dti-1420	57	31	ipilimumab	ipilimumab	NOUN
dti-1420	57	32	(	(	PUNCT
dti-1420	57	33	yervoy	yervoy	NOUN
dti-1420	57	34	;	;	PUNCT
dti-1420	57	35	bristol	bristol	PROPN
dti-1420	57	36	-	-	PUNCT
dti-1420	57	37	myers	myers	PROPN
dti-1420	57	38	squibb	squibb	PROPN
dti-1420	57	39	)	)	PUNCT
dti-1420	57	40	,	,	PUNCT
dti-1420	57	41	nivolumab	nivolumab	NOUN
dti-1420	57	42	(	(	PUNCT
dti-1420	57	43	opdivo	opdivo	NOUN
dti-1420	57	44	;	;	PUNCT
dti-1420	57	45	bristol	bristol	NOUN
dti-1420	57	46	-	-	PUNCT
dti-1420	57	47	myers	myers	PROPN
dti-1420	57	48	squibb	squibb	PROPN
dti-1420	57	49	)	)	PUNCT
dti-1420	57	50	,	,	PUNCT
dti-1420	57	51	and	and	CCONJ
dti-1420	57	52	pembrolizumab	pembrolizumab	NOUN
dti-1420	57	53	(	(	PUNCT
dti-1420	57	54	keytruda	keytruda	NOUN
dti-1420	57	55	;	;	PUNCT
dti-1420	57	56	merck	merck	PROPN
dti-1420	57	57	sharp	sharp	PROPN
dti-1420	57	58	&	&	CCONJ
dti-1420	57	59	dohme	dohme	PROPN
dti-1420	57	60	corp	corp	PROPN
dti-1420	57	61	)	)	PUNCT
dti-1420	57	62	were	be	AUX
dti-1420	57	63	shown	show	VERB
dti-1420	57	64	to	to	PART
dti-1420	57	65	prolong	prolong	VERB
dti-1420	57	66	progression	progression	NOUN
dti-1420	57	67	free	free	ADJ
dti-1420	57	68	and	and	CCONJ
dti-1420	57	69	overall	overall	ADJ
dti-1420	57	70	survival	survival	NOUN
dti-1420	57	71	compared	compare	VERB
dti-1420	57	72	with	with	ADP
dti-1420	57	73	chemotherapy.4	chemotherapy.4	PROPN
dti-1420	57	74	pembrolizumab	pembrolizumab	NOUN
dti-1420	57	75	is	be	AUX
dti-1420	57	76	a	a	DET
dti-1420	57	77	humanized	humanize	VERB
dti-1420	57	78	igg4	igg4	NOUN
dti-1420	57	79	mab	mab	NOUN
dti-1420	57	80	raised	raise	VERB
dti-1420	57	81	against	against	ADP
dti-1420	57	82	the	the	DET
dti-1420	57	83	programmed	program	VERB
dti-1420	57	84	cell	cell	NOUN
dti-1420	57	85	death	death	NOUN
dti-1420	57	86	protein	protein	NOUN
dti-1420	57	87	1	1	NUM
dti-1420	57	88	(	(	PUNCT
dti-1420	57	89	pd-1	pd-1	ADJ
dti-1420	57	90	)	)	PUNCT
dti-1420	57	91	immune	immune	ADJ
dti-1420	57	92	checkpoint	checkpoint	NOUN
dti-1420	57	93	,	,	PUNCT
dti-1420	57	94	recently	recently	ADV
dti-1420	57	95	approved	approve	VERB
dti-1420	57	96	by	by	ADP
dti-1420	57	97	the	the	DET
dti-1420	57	98	us	us	PROPN
dti-1420	57	99	food	food	NOUN
dti-1420	57	100	and	and	CCONJ
dti-1420	57	101	drug	drug	NOUN
dti-1420	57	102	administration	administration	NOUN
dti-1420	57	103	and	and	CCONJ
dti-1420	57	104	the	the	DET
dti-1420	57	105	european	european	PROPN
dti-1420	57	106	medicines	medicine	NOUN
dti-1420	57	107	agency	agency	NOUN
dti-1420	57	108	for	for	ADP
dti-1420	57	109	the	the	DET
dti-1420	57	110	treatment	treatment	NOUN
dti-1420	57	111	of	of	ADP
dti-1420	57	112	advanced	advanced	ADJ
dti-1420	57	113	melanoma	melanoma	NOUN
dti-1420	57	114	,	,	PUNCT
dti-1420	57	115	as	as	ADP
dti-1420	57	116	a	a	DET
dti-1420	57	117	result	result	NOUN
dti-1420	57	118	of	of	ADP
dti-1420	57	119	a	a	DET
dti-1420	57	120	randomized	randomized	ADJ
dti-1420	57	121	controlled	control	VERB
dti-1420	57	122	phase	phase	NOUN
dti-1420	57	123	iii	iii	NOUN
dti-1420	57	124	trial	trial	NOUN
dti-1420	57	125	showing	show	VERB
dti-1420	57	126	improved	improve	VERB
dti-1420	57	127	overall	overall	ADJ
dti-1420	57	128	survival.5	survival.5	NOUN
dti-1420	57	129	pd-1	pd-1	ADV
dti-1420	57	130	is	be	AUX
dti-1420	57	131	a	a	DET
dti-1420	57	132	cell	cell	NOUN
dti-1420	57	133	surface	surface	NOUN
dti-1420	57	134	receptor	receptor	NOUN
dti-1420	57	135	that	that	PRON
dti-1420	57	136	belongs	belong	VERB
dti-1420	57	137	to	to	ADP
dti-1420	57	138	the	the	DET
dti-1420	57	139	immunoglobulin	immunoglobulin	NOUN
dti-1420	57	140	superfamily	superfamily	ADV
dti-1420	57	141	and	and	CCONJ
dti-1420	57	142	is	be	AUX
dti-1420	57	143	normally	normally	ADV
dti-1420	57	144	expressed	express	VERB
dti-1420	57	145	on	on	ADP
dti-1420	57	146	b	b	NOUN
dti-1420	57	147	-	-	PUNCT
dti-1420	57	148	cells,6	cells,6	ADJ
dti-1420	57	149	t	t	NOUN
dti-1420	57	150	-	-	PUNCT
dti-1420	57	151	cells,7	cells,7	NOUN
dti-1420	57	152	and	and	CCONJ
dti-1420	57	153	macrophages.8	macrophages.8	PROPN
dti-1420	57	154	pd-1	pd-1	ADJ
dti-1420	57	155	and	and	CCONJ
dti-1420	57	156	its	its	PRON
dti-1420	57	157	ligands	ligand	NOUN
dti-1420	57	158	,	,	PUNCT
dti-1420	57	159	namely	namely	ADV
dti-1420	57	160	,	,	PUNCT
dti-1420	57	161	programmed	program	VERB
dti-1420	57	162	cell	cell	NOUN
dti-1420	57	163	death	death	NOUN
dti-1420	57	164	ligand	ligand	NOUN
dti-1420	57	165	1	1	NUM
dti-1420	57	166	(	(	PUNCT
dti-1420	57	167	pd	pd	NOUN
dti-1420	57	168	-	-	PUNCT
dti-1420	57	169	l1	l1	NOUN
dti-1420	57	170	)	)	PUNCT
dti-1420	57	171	and	and	CCONJ
dti-1420	57	172	2	2	NUM
dti-1420	57	173	(	(	PUNCT
dti-1420	57	174	pd	pd	NOUN
dti-1420	57	175	-	-	NOUN
dti-1420	57	176	l2	l2	NOUN
dti-1420	57	177	)	)	PUNCT
dti-1420	57	178	,	,	PUNCT
dti-1420	57	179	have	have	AUX
dti-1420	57	180	been	be	AUX
dti-1420	57	181	found	find	VERB
dti-1420	57	182	to	to	PART
dti-1420	57	183	be	be	AUX
dti-1420	57	184	abnormally	abnormally	ADV
dti-1420	57	185	expressed	express	VERB
dti-1420	57	186	by	by	ADP
dti-1420	57	187	tumor	tumor	NOUN
dti-1420	57	188	cells.9	cells.9	PROPN
dti-1420	57	189	these	these	DET
dti-1420	57	190	molecules	molecule	NOUN
dti-1420	57	191	play	play	VERB
dti-1420	57	192	an	an	DET
dti-1420	57	193	important	important	ADJ
dti-1420	57	194	role	role	NOUN
dti-1420	57	195	in	in	ADP
dti-1420	57	196	inhibiting	inhibit	VERB
dti-1420	57	197	antitumor	antitumor	PROPN
dti-1420	57	198	immune	immune	ADJ
dti-1420	57	199	responses	response	NOUN
dti-1420	57	200	and	and	CCONJ
dti-1420	57	201	are	be	AUX
dti-1420	57	202	responsible	responsible	ADJ
dti-1420	57	203	for	for	ADP
dti-1420	57	204	the	the	DET
dti-1420	57	205	immune	immune	ADJ
dti-1420	57	206	evasion	evasion	NOUN
dti-1420	57	207	of	of	ADP
dti-1420	57	208	cancer	cancer	NOUN
dti-1420	57	209	cells	cell	NOUN
dti-1420	57	210	by	by	ADP
dti-1420	57	211	the	the	DET
dti-1420	57	212	cytotoxic	cytotoxic	ADJ
dti-1420	57	213	effector	effector	NOUN
dti-1420	57	214	immune	immune	ADJ
dti-1420	57	215	cells	cell	NOUN
dti-1420	57	216	.	.	PUNCT
dti-1420	58	1	mab	mab	NOUN
dti-1420	58	2	therapies	therapy	NOUN
dti-1420	58	3	against	against	ADP
dti-1420	58	4	the	the	PRON
dti-1420	58	5	pd-1	pd-1	ADJ
dti-1420	58	6	can	can	AUX
dti-1420	58	7	reverse	reverse	VERB
dti-1420	58	8	immune	immune	ADJ
dti-1420	58	9	tolerance	tolerance	NOUN
dti-1420	58	10	and	and	CCONJ
dti-1420	58	11	achieve	achieve	VERB
dti-1420	58	12	high	high	ADJ
dti-1420	58	13	tumor	tumor	NOUN
dti-1420	58	14	response	response	NOUN
dti-1420	58	15	rates	rate	NOUN
dti-1420	58	16	and	and	CCONJ
dti-1420	58	17	improvement	improvement	NOUN
dti-1420	58	18	of	of	ADP
dti-1420	58	19	survival.10	survival.10	ADP
dti-1420	58	20	the	the	DET
dti-1420	58	21	therapeutic	therapeutic	ADJ
dti-1420	58	22	effects	effect	NOUN
dti-1420	58	23	of	of	ADP
dti-1420	58	24	mabs	mab	NOUN
dti-1420	58	25	are	be	AUX
dti-1420	58	26	not	not	PART
dti-1420	58	27	fully	fully	ADV
dti-1420	58	28	understood	understand	VERB
dti-1420	58	29	,	,	PUNCT
dti-1420	58	30	but	but	CCONJ
dti-1420	58	31	they	they	PRON
dti-1420	58	32	are	be	AUX
dti-1420	58	33	mediated	mediate	VERB
dti-1420	58	34	through	through	ADP
dti-1420	58	35	direct	direct	ADJ
dti-1420	58	36	signaling	signaling	NOUN
dti-1420	58	37	,	,	PUNCT
dti-1420	58	38	complementdependent	complementdependent	ADJ
dti-1420	58	39	cellular	cellular	ADJ
dti-1420	58	40	cytotoxicity	cytotoxicity	NOUN
dti-1420	58	41	,	,	PUNCT
dti-1420	58	42	and	and	CCONJ
dti-1420	58	43	antibody	antibody	NOUN
dti-1420	58	44	-	-	PUNCT
dti-1420	58	45	dependent	dependent	ADJ
dti-1420	58	46	cellular	cellular	ADJ
dti-1420	58	47	cytotoxicity.11	cytotoxicity.11	NOUN
dti-1420	58	48	pemprolizumab	pemprolizumab	NOUN
dti-1420	58	49	(	(	PUNCT
dti-1420	58	50	previously	previously	ADV
dti-1420	58	51	known	know	VERB
dti-1420	58	52	as	as	ADP
dti-1420	58	53	mk-3475	mk-3475	NOUN
dti-1420	58	54	or	or	CCONJ
dti-1420	58	55	lambrolizumab	lambrolizumab	NOUN
dti-1420	58	56	)	)	PUNCT
dti-1420	58	57	is	be	AUX
dti-1420	58	58	a	a	DET
dti-1420	58	59	humanized	humanize	VERB
dti-1420	58	60	monoclonal	monoclonal	NOUN
dti-1420	58	61	igg4	igg4	NOUN
dti-1420	58	62	–	–	PUNCT
dti-1420	58	63	kappa	kappa	ADJ
dti-1420	58	64	isotype	isotype	NOUN
dti-1420	58	65	antibody	antibody	NOUN
dti-1420	58	66	.	.	PUNCT
dti-1420	59	1	its	its	PRON
dti-1420	59	2	variable	variable	ADJ
dti-1420	59	3	region	region	NOUN
dti-1420	59	4	sequences	sequence	NOUN
dti-1420	59	5	were	be	AUX
dti-1420	59	6	derived	derive	VERB
dti-1420	59	7	from	from	ADP
dti-1420	59	8	a	a	DET
dti-1420	59	9	very	very	ADV
dti-1420	59	10	high	high	ADJ
dti-1420	59	11	-	-	PUNCT
dti-1420	59	12	affinity	affinity	NOUN
dti-1420	59	13	mouse	mouse	NOUN
dti-1420	59	14	antihuman	antihuman	NOUN
dti-1420	59	15	pd-1	pd-1	ADP
dti-1420	59	16	antibody	antibody	NOUN
dti-1420	59	17	(	(	PUNCT
dti-1420	59	18	dissociation	dissociation	NOUN
dti-1420	59	19	constant	constant	ADJ
dti-1420	59	20	,	,	PUNCT
dti-1420	59	21	28	28	NUM
dti-1420	59	22	 	 	SPACE
dti-1420	59	23	pm	pm	NOUN
dti-1420	59	24	)	)	PUNCT
dti-1420	59	25	that	that	PRON
dti-1420	59	26	was	be	AUX
dti-1420	59	27	grafted	graft	VERB
dti-1420	59	28	into	into	ADP
dti-1420	59	29	a	a	DET
dti-1420	59	30	human	human	ADJ
dti-1420	59	31	igg4	igg4	NOUN
dti-1420	59	32	immunoglobulin	immunoglobulin	NOUN
dti-1420	59	33	with	with	ADP
dti-1420	59	34	a	a	DET
dti-1420	59	35	stabilizing	stabilize	VERB
dti-1420	59	36	s228p	s228p	PROPN
dti-1420	59	37	fc	fc	PROPN
dti-1420	59	38	alteration	alteration	NOUN
dti-1420	59	39	that	that	PRON
dti-1420	59	40	does	do	AUX
dti-1420	59	41	not	not	PART
dti-1420	59	42	engage	engage	VERB
dti-1420	59	43	fc	fc	NOUN
dti-1420	59	44	receptors	receptor	NOUN
dti-1420	59	45	or	or	CCONJ
dti-1420	59	46	activate	activate	VERB
dti-1420	59	47	complement	complement	NOUN
dti-1420	59	48	,	,	PUNCT
dti-1420	59	49	thus	thus	ADV
dti-1420	59	50	avoiding	avoid	VERB
dti-1420	59	51	cytotoxic	cytotoxic	ADJ
dti-1420	59	52	effects	effect	NOUN
dti-1420	59	53	of	of	ADP
dti-1420	59	54	the	the	DET
dti-1420	59	55	antibody	antibody	NOUN
dti-1420	59	56	when	when	SCONJ
dti-1420	59	57	it	it	PRON
dti-1420	59	58	binds	bind	VERB
dti-1420	59	59	to	to	ADP
dti-1420	59	60	the	the	DET
dti-1420	59	61	pd-1	pd-1	ADJ
dti-1420	59	62	receptor	receptor	NOUN
dti-1420	59	63	of	of	ADP
dti-1420	59	64	t	t	PROPN
dti-1420	59	65	-	-	PUNCT
dti-1420	59	66	cells	cell	NOUN
dti-1420	59	67	that	that	PRON
dti-1420	59	68	are	be	AUX
dti-1420	59	69	intended	intend	VERB
dti-1420	59	70	to	to	PART
dti-1420	59	71	activate	activate	VERB
dti-1420	59	72	against	against	ADP
dti-1420	59	73	tumor	tumor	NOUN
dti-1420	59	74	cells.12	cells.12	NOUN
dti-1420	59	75	it	it	PRON
dti-1420	59	76	is	be	AUX
dti-1420	59	77	reasonable	reasonable	ADJ
dti-1420	59	78	to	to	PART
dti-1420	59	79	assume	assume	VERB
dti-1420	59	80	that	that	SCONJ
dti-1420	59	81	the	the	DET
dti-1420	59	82	mechanism	mechanism	NOUN
dti-1420	59	83	of	of	ADP
dti-1420	59	84	action	action	NOUN
dti-1420	59	85	and	and	CCONJ
dti-1420	59	86	the	the	DET
dti-1420	59	87	resulting	result	VERB
dti-1420	59	88	side	side	NOUN
dti-1420	59	89	effects	effect	NOUN
dti-1420	59	90	of	of	ADP
dti-1420	59	91	pembrolizumab	pembrolizumab	NOUN
dti-1420	59	92	are	be	AUX
dti-1420	59	93	mediated	mediate	VERB
dti-1420	59	94	through	through	ADP
dti-1420	59	95	pd-1	pd-1	ADV
dti-1420	59	96	direct	direct	ADJ
dti-1420	59	97	signaling	signaling	NOUN
dti-1420	59	98	on	on	ADP
dti-1420	59	99	t	t	PROPN
dti-1420	59	100	-	-	PUNCT
dti-1420	59	101	cells	cell	NOUN
dti-1420	59	102	or	or	CCONJ
dti-1420	59	103	macrophages	macrophage	NOUN
dti-1420	59	104	.	.	PUNCT
dti-1420	60	1	cryptogenic	cryptogenic	ADJ
dti-1420	60	2	organizing	organizing	NOUN
dti-1420	60	3	pneumonia	pneumonia	NOUN
dti-1420	60	4	(	(	PUNCT
dti-1420	60	5	cop	cop	NOUN
dti-1420	60	6	)	)	PUNCT
dti-1420	60	7	,	,	PUNCT
dti-1420	60	8	the	the	DET
dti-1420	60	9	idiopathic	idiopathic	ADJ
dti-1420	60	10	form	form	NOUN
dti-1420	60	11	of	of	ADP
dti-1420	60	12	op	op	NOUN
dti-1420	60	13	(	(	PUNCT
dti-1420	60	14	formerly	formerly	ADV
dti-1420	60	15	called	call	VERB
dti-1420	60	16	bronchiolitis	bronchiolitis	ADJ
dti-1420	60	17	obliterans	obliteran	NOUN
dti-1420	60	18	op	op	NOUN
dti-1420	60	19	)	)	PUNCT
dti-1420	60	20	,	,	PUNCT
dti-1420	60	21	is	be	AUX
dti-1420	60	22	a	a	DET
dti-1420	60	23	type	type	NOUN
dti-1420	60	24	of	of	ADP
dti-1420	60	25	diffuse	diffuse	ADJ
dti-1420	60	26	interstitial	interstitial	ADJ
dti-1420	60	27	lung	lung	NOUN
dti-1420	60	28	disease	disease	NOUN
dti-1420	60	29	that	that	PRON
dti-1420	60	30	affects	affect	VERB
dti-1420	60	31	the	the	DET
dti-1420	60	32	distal	distal	ADJ
dti-1420	60	33	bronchioles	bronchiole	NOUN
dti-1420	60	34	,	,	PUNCT
dti-1420	60	35	respiratory	respiratory	ADJ
dti-1420	60	36	bronchioles	bronchiole	NOUN
dti-1420	60	37	,	,	PUNCT
dti-1420	60	38	alveolar	alveolar	ADJ
dti-1420	60	39	ducts	duct	NOUN
dti-1420	60	40	,	,	PUNCT
dti-1420	60	41	and	and	CCONJ
dti-1420	60	42	alveolar	alveolar	ADJ
dti-1420	60	43	walls	wall	NOUN
dti-1420	60	44	.	.	PUNCT
dti-1420	61	1	the	the	DET
dti-1420	61	2	primary	primary	ADJ
dti-1420	61	3	area	area	NOUN
dti-1420	61	4	of	of	ADP
dti-1420	61	5	injury	injury	NOUN
dti-1420	61	6	is	be	AUX
dti-1420	61	7	within	within	ADP
dti-1420	61	8	the	the	DET
dti-1420	61	9	alveolar	alveolar	ADJ
dti-1420	61	10	wall	wall	NOUN
dti-1420	61	11	.	.	PUNCT
dti-1420	62	1	since	since	SCONJ
dti-1420	62	2	many	many	ADJ
dti-1420	62	3	cases	case	NOUN
dti-1420	62	4	of	of	ADP
dti-1420	62	5	cop	cop	NOUN
dti-1420	62	6	are	be	AUX
dti-1420	62	7	secondary	secondary	ADJ
dti-1420	62	8	,	,	PUNCT
dti-1420	62	9	it	it	PRON
dti-1420	62	10	is	be	AUX
dti-1420	62	11	more	more	ADV
dti-1420	62	12	proper	proper	ADJ
dti-1420	62	13	to	to	PART
dti-1420	62	14	use	use	VERB
dti-1420	62	15	the	the	DET
dti-1420	62	16	term	term	NOUN
dti-1420	62	17	op	op	NOUN
dti-1420	62	18	associated	associate	VERB
dti-1420	62	19	with	with	ADP
dti-1420	62	20	the	the	DET
dti-1420	62	21	name	name	NOUN
dti-1420	62	22	of	of	ADP
dti-1420	62	23	the	the	DET
dti-1420	62	24	secondary	secondary	ADJ
dti-1420	62	25	cause.13	cause.13	PROPN
dti-1420	62	26	histopathologic	histopathologic	PROPN
dti-1420	62	27	study	study	NOUN
dti-1420	62	28	through	through	ADP
dti-1420	62	29	lung	lung	NOUN
dti-1420	62	30	biopsy	biopsy	NOUN
dti-1420	62	31	via	via	ADP
dti-1420	62	32	videoassisted	videoassiste	VERB
dti-1420	62	33	thoracoscopic	thoracoscopic	ADJ
dti-1420	62	34	surgery	surgery	NOUN
dti-1420	62	35	or	or	CCONJ
dti-1420	62	36	open	open	ADJ
dti-1420	62	37	thoracotomy	thoracotomy	NOUN
dti-1420	62	38	is	be	AUX
dti-1420	62	39	the	the	DET
dti-1420	62	40	optimal	optimal	ADJ
dti-1420	62	41	method	method	NOUN
dti-1420	62	42	for	for	ADP
dti-1420	62	43	establishing	establish	VERB
dti-1420	62	44	the	the	DET
dti-1420	62	45	diagnosis	diagnosis	NOUN
dti-1420	62	46	of	of	ADP
dti-1420	62	47	cop	cop	NOUN
dti-1420	62	48	,	,	PUNCT
dti-1420	62	49	in	in	ADP
dti-1420	62	50	order	order	NOUN
dti-1420	62	51	to	to	PART
dti-1420	62	52	have	have	AUX
dti-1420	62	53	enough	enough	ADJ
dti-1420	62	54	tissue	tissue	NOUN
dti-1420	62	55	for	for	SCONJ
dti-1420	62	56	the	the	DET
dti-1420	62	57	pathologist	pathologist	NOUN
dti-1420	62	58	to	to	PART
dti-1420	62	59	exclude	exclude	VERB
dti-1420	62	60	other	other	ADJ
dti-1420	62	61	processes	process	NOUN
dti-1420	62	62	.	.	PUNCT
dti-1420	63	1	because	because	SCONJ
dti-1420	63	2	of	of	ADP
dti-1420	63	3	the	the	DET
dti-1420	63	4	low	low	ADJ
dti-1420	63	5	oxygen	oxygen	NOUN
dti-1420	63	6	saturation	saturation	NOUN
dti-1420	63	7	level	level	NOUN
dti-1420	63	8	,	,	PUNCT
dti-1420	63	9	we	we	PRON
dti-1420	63	10	selected	select	VERB
dti-1420	63	11	to	to	PART
dti-1420	63	12	combine	combine	VERB
dti-1420	63	13	the	the	DET
dti-1420	63	14	cytological	cytological	ADJ
dti-1420	63	15	profile	profile	NOUN
dti-1420	63	16	of	of	ADP
dti-1420	63	17	bal	bal	PROPN
dti-1420	63	18	with	with	ADP
dti-1420	63	19	figure	figure	NOUN
dti-1420	63	20	1	1	NUM
dti-1420	63	21	.	.	PUNCT
dti-1420	64	1	patient	patient	NOUN
dti-1420	64	2	’s	’s	PART
dti-1420	64	3	computed	compute	VERB
dti-1420	64	4	tomography	tomography	NOUN
dti-1420	64	5	of	of	ADP
dti-1420	64	6	chest	chest	NOUN
dti-1420	64	7	indicating	indicate	VERB
dti-1420	64	8	(	(	PUNCT
dti-1420	64	9	a	a	PRON
dti-1420	64	10	)	)	PUNCT
dti-1420	64	11	baseline	baseline	NOUN
dti-1420	64	12	ct	ct	NUM
dti-1420	64	13	scan	scan	NOUN
dti-1420	64	14	before	before	ADP
dti-1420	64	15	pembrolizumab	pembrolizumab	NOUN
dti-1420	64	16	therapy	therapy	NOUN
dti-1420	64	17	,	,	PUNCT
dti-1420	64	18	(	(	PUNCT
dti-1420	64	19	b	b	X
dti-1420	64	20	)	)	PUNCT
dti-1420	64	21	reverse	reverse	VERB
dti-1420	64	22	halo	halo	NOUN
dti-1420	64	23	sign	sign	NOUN
dti-1420	64	24	(	(	PUNCT
dti-1420	64	25	dotted	dotted	ADJ
dti-1420	64	26	arrow	arrow	NOUN
dti-1420	64	27	)	)	PUNCT
dti-1420	64	28	and	and	CCONJ
dti-1420	64	29	consolidation	consolidation	NOUN
dti-1420	64	30	with	with	ADP
dti-1420	64	31	air	air	NOUN
dti-1420	64	32	bronchogram	bronchogram	PROPN
dti-1420	64	33	(	(	PUNCT
dti-1420	64	34	straight	straight	ADJ
dti-1420	64	35	arrow	arrow	NOUN
dti-1420	64	36	)	)	PUNCT
dti-1420	64	37	features	feature	NOUN
dti-1420	64	38	of	of	ADP
dti-1420	64	39	op	op	NOUN
dti-1420	64	40	following	follow	VERB
dti-1420	64	41	therapy	therapy	NOUN
dti-1420	64	42	of	of	ADP
dti-1420	64	43	pembrolizumab	pembrolizumab	NOUN
dti-1420	64	44	,	,	PUNCT
dti-1420	64	45	and	and	CCONJ
dti-1420	64	46	(	(	PUNCT
dti-1420	64	47	c	c	NOUN
dti-1420	64	48	)	)	PUNCT
dti-1420	64	49	follow	follow	NOUN
dti-1420	64	50	-	-	PUNCT
dti-1420	64	51	up	up	NOUN
dti-1420	64	52	ct	ct	NOUN
dti-1420	64	53	scan	scan	NOUN
dti-1420	64	54	indicating	indicate	VERB
dti-1420	64	55	complete	complete	ADJ
dti-1420	64	56	resolution	resolution	NOUN
dti-1420	64	57	of	of	ADP
dti-1420	64	58	the	the	DET
dti-1420	64	59	organized	organized	ADJ
dti-1420	64	60	pneumonia	pneumonia	NOUN
dti-1420	64	61	,	,	PUNCT
dti-1420	64	62	one	one	NUM
dti-1420	64	63	month	month	NOUN
dti-1420	64	64	after	after	ADP
dti-1420	64	65	the	the	DET
dti-1420	64	66	steroid	steroid	NOUN
dti-1420	64	67	therapy	therapy	NOUN
dti-1420	64	68	.	.	PUNCT
dti-1420	65	1	metastatic	metastatic	ADJ
dti-1420	65	2	lesion	lesion	NOUN
dti-1420	65	3	in	in	ADP
dti-1420	65	4	the	the	DET
dti-1420	65	5	right	right	ADJ
dti-1420	65	6	middle	middle	ADJ
dti-1420	65	7	lobe	lobe	PROPN
dti-1420	65	8	.	.	PUNCT
dti-1420	66	1	http://www.la-press.com	http://www.la-press.com	X
dti-1420	67	1	http://www.la-press.com/drug-target-insights-journal-j23	http://www.la-press.com/drug-target-insights-journal-j23	PROPN
dti-1420	67	2	op	op	NOUN
dti-1420	67	3	in	in	ADP
dti-1420	67	4	pembrolizumab	pembrolizumab	NOUN
dti-1420	67	5	11drug	11drug	PROPN
dti-1420	67	6	target	target	NOUN
dti-1420	67	7	insights	insight	VERB
dti-1420	67	8	2016:10	2016:10	NUM
dti-1420	67	9	characteristic	characteristic	ADJ
dti-1420	67	10	clinical	clinical	ADJ
dti-1420	67	11	and	and	CCONJ
dti-1420	67	12	imaging	imaging	NOUN
dti-1420	67	13	features	feature	NOUN
dti-1420	67	14	.	.	PUNCT
dti-1420	68	1	a	a	DET
dti-1420	68	2	previous	previous	ADJ
dti-1420	68	3	study	study	NOUN
dti-1420	68	4	has	have	AUX
dti-1420	68	5	already	already	ADV
dti-1420	68	6	described	describe	VERB
dti-1420	68	7	in	in	ADP
dti-1420	68	8	detail	detail	NOUN
dti-1420	68	9	the	the	DET
dti-1420	68	10	cytological	cytological	ADJ
dti-1420	68	11	and	and	CCONJ
dti-1420	68	12	immunocytological	immunocytological	ADJ
dti-1420	68	13	profile	profile	NOUN
dti-1420	68	14	of	of	ADP
dti-1420	68	15	bal	bal	PROPN
dti-1420	68	16	in	in	ADP
dti-1420	68	17	cop	cop	NOUN
dti-1420	68	18	,	,	PUNCT
dti-1420	68	19	which	which	PRON
dti-1420	68	20	include	include	VERB
dti-1420	68	21	foamy	foamy	ADJ
dti-1420	68	22	macrophages	macrophage	NOUN
dti-1420	68	23	,	,	PUNCT
dti-1420	68	24	mast	mast	NOUN
dti-1420	68	25	cells	cell	NOUN
dti-1420	68	26	,	,	PUNCT
dti-1420	68	27	plasma	plasma	NOUN
dti-1420	68	28	cells	cell	NOUN
dti-1420	68	29	,	,	PUNCT
dti-1420	68	30	a	a	DET
dti-1420	68	31	decreased	decrease	VERB
dti-1420	68	32	cd4	cd4	PROPN
dti-1420	68	33	/	/	SYM
dti-1420	68	34	cd8	cd8	PROPN
dti-1420	68	35	t	t	PROPN
dti-1420	68	36	-	-	PUNCT
dti-1420	68	37	cell	cell	NOUN
dti-1420	68	38	ratio	ratio	NOUN
dti-1420	68	39	,	,	PUNCT
dti-1420	68	40	an	an	DET
dti-1420	68	41	increase	increase	NOUN
dti-1420	68	42	in	in	ADP
dti-1420	68	43	activated	activate	VERB
dti-1420	68	44	t	t	PROPN
dti-1420	68	45	-	-	PUNCT
dti-1420	68	46	lymphocytes	lymphocyte	NOUN
dti-1420	68	47	based	base	VERB
dti-1420	68	48	on	on	ADP
dti-1420	68	49	hla	hla	PROPN
dti-1420	68	50	-	-	PUNCT
dti-1420	68	51	dr	dr	PROPN
dti-1420	68	52	or	or	CCONJ
dti-1420	68	53	interleukin-2	interleukin-2	NUM
dti-1420	68	54	receptor	receptor	NOUN
dti-1420	68	55	expression	expression	NOUN
dti-1420	68	56	and	and	CCONJ
dti-1420	68	57	a	a	DET
dti-1420	68	58	lymphocyte	lymphocyte	ADJ
dti-1420	68	59	increase	increase	NOUN
dti-1420	68	60	of	of	ADP
dti-1420	68	61	20%–40	20%–40	NUM
dti-1420	68	62	%	%	NOUN
dti-1420	68	63	also	also	ADV
dti-1420	68	64	documented	document	VERB
dti-1420	68	65	in	in	ADP
dti-1420	68	66	our	our	PRON
dti-1420	68	67	patient	patient	NOUN
dti-1420	68	68	with	with	ADP
dti-1420	68	69	bronchiolitis	bronchiolitis	ADJ
dti-1420	68	70	obliterans	obliteran	NOUN
dti-1420	68	71	.	.	PUNCT
dti-1420	69	1	the	the	DET
dti-1420	69	2	most	most	ADV
dti-1420	69	3	commonly	commonly	ADV
dti-1420	69	4	occurring	occur	VERB
dti-1420	69	5	clinical	clinical	ADJ
dti-1420	69	6	findings	finding	NOUN
dti-1420	69	7	in	in	ADP
dti-1420	69	8	cop	cop	NOUN
dti-1420	69	9	are	be	AUX
dti-1420	69	10	similar	similar	ADJ
dti-1420	69	11	to	to	ADP
dti-1420	69	12	our	our	PRON
dti-1420	69	13	patient	patient	NOUN
dti-1420	69	14	’s	’s	PART
dti-1420	69	15	symptoms	symptom	NOUN
dti-1420	69	16	,	,	PUNCT
dti-1420	69	17	including	include	VERB
dti-1420	69	18	nonproductive	nonproductive	ADJ
dti-1420	69	19	persistent	persistent	ADJ
dti-1420	69	20	cough	cough	NOUN
dti-1420	69	21	,	,	PUNCT
dti-1420	69	22	dyspnea	dyspnea	NOUN
dti-1420	69	23	,	,	PUNCT
dti-1420	69	24	and	and	CCONJ
dti-1420	69	25	malaise	malaise	NOUN
dti-1420	69	26	without	without	ADP
dti-1420	69	27	fever.14	fever.14	NOUN
dti-1420	69	28	since	since	SCONJ
dti-1420	69	29	the	the	DET
dti-1420	69	30	most	most	ADV
dti-1420	69	31	common	common	ADJ
dti-1420	69	32	manifestations	manifestation	NOUN
dti-1420	69	33	are	be	AUX
dti-1420	69	34	nonspecific	nonspecific	ADJ
dti-1420	69	35	,	,	PUNCT
dti-1420	69	36	diagnosis	diagnosis	NOUN
dti-1420	69	37	is	be	AUX
dti-1420	69	38	often	often	ADV
dti-1420	69	39	delayed	delay	VERB
dti-1420	69	40	(	(	PUNCT
dti-1420	69	41	6–13	6–13	NOUN
dti-1420	69	42	weeks	week	NOUN
dti-1420	69	43	)	)	PUNCT
dti-1420	69	44	,	,	PUNCT
dti-1420	69	45	and	and	CCONJ
dti-1420	69	46	similar	similar	ADJ
dti-1420	69	47	to	to	ADP
dti-1420	69	48	our	our	PRON
dti-1420	69	49	patient	patient	NOUN
dti-1420	69	50	,	,	PUNCT
dti-1420	69	51	a	a	DET
dti-1420	69	52	lack	lack	NOUN
dti-1420	69	53	of	of	ADP
dti-1420	69	54	response	response	NOUN
dti-1420	69	55	to	to	ADP
dti-1420	69	56	empiric	empiric	VERB
dti-1420	69	57	antibiotics	antibiotic	NOUN
dti-1420	69	58	for	for	ADP
dti-1420	69	59	community	community	NOUN
dti-1420	69	60	-	-	PUNCT
dti-1420	69	61	acquired	acquire	VERB
dti-1420	69	62	pneumonia	pneumonia	NOUN
dti-1420	69	63	may	may	AUX
dti-1420	69	64	be	be	AUX
dti-1420	69	65	the	the	DET
dti-1420	69	66	initial	initial	ADJ
dti-1420	69	67	clue	clue	NOUN
dti-1420	69	68	to	to	ADP
dti-1420	69	69	the	the	DET
dti-1420	69	70	presence	presence	NOUN
dti-1420	69	71	of	of	ADP
dti-1420	69	72	a	a	DET
dti-1420	69	73	noninfectious	noninfectious	ADJ
dti-1420	69	74	,	,	PUNCT
dti-1420	69	75	inflammatory	inflammatory	ADJ
dti-1420	69	76	pneumonia.15	pneumonia.15	NOUN
dti-1420	69	77	similar	similar	ADJ
dti-1420	69	78	to	to	ADP
dti-1420	69	79	that	that	PRON
dti-1420	69	80	in	in	ADP
dti-1420	69	81	our	our	PRON
dti-1420	69	82	patient	patient	NOUN
dti-1420	69	83	,	,	PUNCT
dti-1420	69	84	hrct	hrct	PROPN
dti-1420	69	85	has	have	VERB
dti-1420	69	86	findings	finding	NOUN
dti-1420	69	87	that	that	PRON
dti-1420	69	88	are	be	AUX
dti-1420	69	89	characteristic	characteristic	ADJ
dti-1420	69	90	for	for	ADP
dti-1420	69	91	cop	cop	NOUN
dti-1420	69	92	and	and	CCONJ
dti-1420	69	93	include	include	VERB
dti-1420	69	94	peripheral	peripheral	ADJ
dti-1420	69	95	bilateral	bilateral	ADJ
dti-1420	69	96	patchy	patchy	ADJ
dti-1420	69	97	opacities	opacity	NOUN
dti-1420	69	98	,	,	PUNCT
dti-1420	69	99	more	more	ADV
dti-1420	69	100	frequently	frequently	ADV
dti-1420	69	101	in	in	ADP
dti-1420	69	102	the	the	DET
dti-1420	69	103	periphery	periphery	NOUN
dti-1420	69	104	and	and	CCONJ
dti-1420	69	105	in	in	ADP
dti-1420	69	106	the	the	DET
dti-1420	69	107	lower	low	ADJ
dti-1420	69	108	lung	lung	NOUN
dti-1420	69	109	zone	zone	NOUN
dti-1420	69	110	,	,	PUNCT
dti-1420	69	111	air	air	NOUN
dti-1420	69	112	bronchogram	bronchogram	NOUN
dti-1420	69	113	,	,	PUNCT
dti-1420	69	114	and	and	CCONJ
dti-1420	69	115	reverse	reverse	VERB
dti-1420	69	116	halo	halo	NOUN
dti-1420	69	117	sign.16	sign.16	PROPN
dti-1420	69	118	once	once	SCONJ
dti-1420	69	119	the	the	DET
dti-1420	69	120	diagnosis	diagnosis	NOUN
dti-1420	69	121	of	of	ADP
dti-1420	69	122	cop	cop	NOUN
dti-1420	69	123	is	be	AUX
dti-1420	69	124	made	make	VERB
dti-1420	69	125	,	,	PUNCT
dti-1420	69	126	rapid	rapid	ADJ
dti-1420	69	127	clinical	clinical	ADJ
dti-1420	69	128	and	and	CCONJ
dti-1420	69	129	imaging	imaging	NOUN
dti-1420	69	130	improvement	improvement	NOUN
dti-1420	69	131	is	be	AUX
dti-1420	69	132	obtained	obtain	VERB
dti-1420	69	133	with	with	ADP
dti-1420	69	134	corticosteroid	corticosteroid	ADJ
dti-1420	69	135	treatment	treatment	NOUN
dti-1420	69	136	,	,	PUNCT
dti-1420	69	137	but	but	CCONJ
dti-1420	69	138	relapses	relapse	NOUN
dti-1420	69	139	are	be	AUX
dti-1420	69	140	common	common	ADJ
dti-1420	69	141	after	after	ADP
dti-1420	69	142	stopping	stop	VERB
dti-1420	69	143	treatment	treatment	NOUN
dti-1420	69	144	,	,	PUNCT
dti-1420	69	145	indicating	indicate	VERB
dti-1420	69	146	an	an	DET
dti-1420	69	147	established	establish	VERB
dti-1420	69	148	immune	immune	ADJ
dti-1420	69	149	reaction	reaction	NOUN
dti-1420	69	150	requiring	require	VERB
dti-1420	69	151	long	long	ADJ
dti-1420	69	152	-	-	PUNCT
dti-1420	69	153	term	term	NOUN
dti-1420	69	154	therapy.15	therapy.15	NOUN
dti-1420	69	155	when	when	SCONJ
dti-1420	69	156	cop	cop	NOUN
dti-1420	69	157	is	be	AUX
dti-1420	69	158	suspected	suspect	VERB
dti-1420	69	159	in	in	ADP
dti-1420	69	160	cancer	cancer	NOUN
dti-1420	69	161	patients	patient	NOUN
dti-1420	69	162	,	,	PUNCT
dti-1420	69	163	differential	differential	ADJ
dti-1420	69	164	diagnoses	diagnosis	NOUN
dti-1420	69	165	that	that	PRON
dti-1420	69	166	need	need	VERB
dti-1420	69	167	to	to	PART
dti-1420	69	168	be	be	AUX
dti-1420	69	169	considered	consider	VERB
dti-1420	69	170	include	include	VERB
dti-1420	69	171	disease	disease	NOUN
dti-1420	69	172	progression	progression	NOUN
dti-1420	69	173	,	,	PUNCT
dti-1420	69	174	cardiogenic	cardiogenic	ADJ
dti-1420	69	175	edema	edema	NOUN
dti-1420	69	176	,	,	PUNCT
dti-1420	69	177	radiation	radiation	NOUN
dti-1420	69	178	pneumonitis	pneumonitis	NOUN
dti-1420	69	179	,	,	PUNCT
dti-1420	69	180	allergies	allergy	NOUN
dti-1420	69	181	,	,	PUNCT
dti-1420	69	182	pulmonary	pulmonary	ADJ
dti-1420	69	183	hemorrhage	hemorrhage	NOUN
dti-1420	69	184	,	,	PUNCT
dti-1420	69	185	and	and	CCONJ
dti-1420	69	186	infections	infection	NOUN
dti-1420	69	187	that	that	PRON
dti-1420	69	188	cause	cause	VERB
dti-1420	69	189	diffuse	diffuse	ADJ
dti-1420	69	190	interstitial	interstitial	ADJ
dti-1420	69	191	infiltrates	infiltrate	NOUN
dti-1420	69	192	in	in	ADP
dti-1420	69	193	the	the	DET
dti-1420	69	194	lungs	lung	NOUN
dti-1420	69	195	such	such	ADJ
dti-1420	69	196	as	as	ADP
dti-1420	69	197	gram	gram	NOUN
dti-1420	69	198	-	-	PUNCT
dti-1420	69	199	negative	negative	ADJ
dti-1420	69	200	or	or	CCONJ
dti-1420	69	201	grampositive	grampositive	ADJ
dti-1420	69	202	bacteria	bacteria	NOUN
dti-1420	69	203	,	,	PUNCT
dti-1420	69	204	fungi	fungus	NOUN
dti-1420	69	205	(	(	PUNCT
dti-1420	69	206	aspergillus	aspergillus	NOUN
dti-1420	69	207	,	,	PUNCT
dti-1420	69	208	candida	candida	PROPN
dti-1420	69	209	,	,	PUNCT
dti-1420	69	210	and	and	CCONJ
dti-1420	69	211	p.	p.	NOUN
dti-1420	69	212	 	 	SPACE
dti-1420	69	213	jirovecii	jirovecii	PROPN
dti-1420	69	214	)	)	PUNCT
dti-1420	69	215	,	,	PUNCT
dti-1420	69	216	parasites	parasite	NOUN
dti-1420	69	217	(	(	PUNCT
dti-1420	69	218	toxoplasma	toxoplasma	NOUN
dti-1420	69	219	gondii	gondii	NOUN
dti-1420	69	220	)	)	PUNCT
dti-1420	69	221	,	,	PUNCT
dti-1420	69	222	or	or	CCONJ
dti-1420	69	223	viruses	virus	NOUN
dti-1420	69	224	(	(	PUNCT
dti-1420	69	225	herpes	herpe	NOUN
dti-1420	69	226	simplex	simplex	NOUN
dti-1420	69	227	,	,	PUNCT
dti-1420	69	228	varicella	varicella	NOUN
dti-1420	69	229	zoster	zoster	NOUN
dti-1420	69	230	,	,	PUNCT
dti-1420	69	231	and	and	CCONJ
dti-1420	69	232	cytomegalovirus).17	cytomegalovirus).17	NOUN
dti-1420	69	233	on	on	ADP
dti-1420	69	234	the	the	DET
dti-1420	69	235	other	other	ADJ
dti-1420	69	236	hand	hand	NOUN
dti-1420	69	237	,	,	PUNCT
dti-1420	69	238	pneumonitis	pneumonitis	NOUN
dti-1420	69	239	in	in	ADP
dti-1420	69	240	cancer	cancer	NOUN
dti-1420	69	241	patients	patient	NOUN
dti-1420	69	242	may	may	AUX
dti-1420	69	243	hold	hold	VERB
dti-1420	69	244	a	a	DET
dti-1420	69	245	heterogeneous	heterogeneous	ADJ
dti-1420	69	246	pathological	pathological	ADJ
dti-1420	69	247	background	background	NOUN
dti-1420	69	248	based	base	VERB
dti-1420	69	249	on	on	ADP
dti-1420	69	250	various	various	ADJ
dti-1420	69	251	antineoplastic	antineoplastic	ADJ
dti-1420	69	252	agents	agent	NOUN
dti-1420	69	253	including	include	VERB
dti-1420	69	254	chemotherapy	chemotherapy	NOUN
dti-1420	69	255	,	,	PUNCT
dti-1420	69	256	such	such	ADJ
dti-1420	69	257	as	as	ADP
dti-1420	69	258	taxanes	taxane	NOUN
dti-1420	69	259	,	,	PUNCT
dti-1420	69	260	targeted	target	VERB
dti-1420	69	261	therapy	therapy	NOUN
dti-1420	69	262	,	,	PUNCT
dti-1420	69	263	such	such	ADJ
dti-1420	69	264	as	as	ADP
dti-1420	69	265	everolimus	everolimus	NOUN
dti-1420	69	266	,	,	PUNCT
dti-1420	69	267	and	and	CCONJ
dti-1420	69	268	mabs	mab	NOUN
dti-1420	69	269	,	,	PUNCT
dti-1420	69	270	such	such	ADJ
dti-1420	69	271	as	as	ADP
dti-1420	69	272	rituximab	rituximab	NOUN
dti-1420	69	273	,	,	PUNCT
dti-1420	69	274	a	a	DET
dti-1420	69	275	chimeric	chimeric	ADJ
dti-1420	69	276	igg1.17	igg1.17	NOUN
dti-1420	69	277	in	in	ADP
dti-1420	69	278	retrospective	retrospective	ADJ
dti-1420	69	279	analysis	analysis	NOUN
dti-1420	69	280	of	of	ADP
dti-1420	69	281	patients	patient	NOUN
dti-1420	69	282	with	with	ADP
dti-1420	69	283	non	non	ADJ
dti-1420	69	284	-	-	ADJ
dti-1420	69	285	hodgkin	hodgkin	ADJ
dti-1420	69	286	lymphoma	lymphoma	NOUN
dti-1420	69	287	treated	treat	VERB
dti-1420	69	288	with	with	ADP
dti-1420	69	289	rituximab	rituximab	NOUN
dti-1420	69	290	,	,	PUNCT
dti-1420	69	291	8	8	NUM
dti-1420	69	292	of	of	ADP
dti-1420	69	293	23	23	NUM
dti-1420	69	294	patients	patient	NOUN
dti-1420	69	295	,	,	PUNCT
dti-1420	69	296	diagnosed	diagnose	VERB
dti-1420	69	297	with	with	ADP
dti-1420	69	298	cop	cop	NOUN
dti-1420	69	299	and	and	CCONJ
dti-1420	69	300	treated	treat	VERB
dti-1420	69	301	with	with	ADP
dti-1420	69	302	corticosteroids	corticosteroid	NOUN
dti-1420	69	303	,	,	PUNCT
dti-1420	69	304	died	die	VERB
dti-1420	69	305	,	,	PUNCT
dti-1420	69	306	indicating	indicate	VERB
dti-1420	69	307	that	that	SCONJ
dti-1420	69	308	cop	cop	NOUN
dti-1420	69	309	although	although	SCONJ
dti-1420	69	310	rare	rare	ADJ
dti-1420	69	311	may	may	AUX
dti-1420	69	312	become	become	VERB
dti-1420	69	313	a	a	DET
dti-1420	69	314	fatal	fatal	ADJ
dti-1420	69	315	pulmonary	pulmonary	NOUN
dti-1420	69	316	toxicity	toxicity	NOUN
dti-1420	69	317	and	and	CCONJ
dti-1420	69	318	the	the	DET
dti-1420	69	319	oncologists	oncologist	NOUN
dti-1420	69	320	or	or	CCONJ
dti-1420	69	321	internists	internist	NOUN
dti-1420	69	322	must	must	AUX
dti-1420	69	323	maintain	maintain	VERB
dti-1420	69	324	a	a	DET
dti-1420	69	325	high	high	ADJ
dti-1420	69	326	index	index	NOUN
dti-1420	69	327	of	of	ADP
dti-1420	69	328	suspicion	suspicion	NOUN
dti-1420	69	329	to	to	PART
dti-1420	69	330	recognize	recognize	VERB
dti-1420	69	331	this	this	DET
dti-1420	69	332	complication	complication	NOUN
dti-1420	69	333	early	early	ADV
dti-1420	69	334	.	.	PUNCT
dti-1420	70	1	little	little	ADJ
dti-1420	70	2	is	be	AUX
dti-1420	70	3	known	know	VERB
dti-1420	70	4	regarding	regard	VERB
dti-1420	70	5	the	the	DET
dti-1420	70	6	clinicopathologic	clinicopathologic	ADJ
dti-1420	70	7	features	feature	NOUN
dti-1420	70	8	of	of	ADP
dti-1420	70	9	pneumonitis	pneumonitis	NOUN
dti-1420	70	10	related	relate	VERB
dti-1420	70	11	to	to	ADP
dti-1420	70	12	the	the	DET
dti-1420	70	13	novel	novel	ADJ
dti-1420	70	14	immune	immune	ADJ
dti-1420	70	15	checkpoint	checkpoint	NOUN
dti-1420	70	16	inhibitors	inhibitor	NOUN
dti-1420	70	17	.	.	PUNCT
dti-1420	71	1	a	a	DET
dti-1420	71	2	recent	recent	ADJ
dti-1420	71	3	study	study	NOUN
dti-1420	71	4	indicated	indicate	VERB
dti-1420	71	5	the	the	DET
dti-1420	71	6	development	development	NOUN
dti-1420	71	7	of	of	ADP
dti-1420	71	8	pneumonitis	pneumonitis	NOUN
dti-1420	71	9	in	in	ADP
dti-1420	71	10	three	three	NUM
dti-1420	71	11	patients	patient	NOUN
dti-1420	71	12	treated	treat	VERB
dti-1420	71	13	with	with	ADP
dti-1420	71	14	nivolumab	nivolumab	NOUN
dti-1420	71	15	,	,	PUNCT
dti-1420	71	16	an	an	DET
dti-1420	71	17	anti	anti	ADJ
dti-1420	71	18	-	-	ADJ
dti-1420	71	19	pd-1	pd-1	ADJ
dti-1420	71	20	mab	mab	NOUN
dti-1420	71	21	,	,	PUNCT
dti-1420	71	22	7–24.3	7–24.3	NUM
dti-1420	71	23	months	month	NOUN
dti-1420	71	24	after	after	ADP
dti-1420	71	25	treatment	treatment	NOUN
dti-1420	71	26	initiation.18	initiation.18	NOUN
dti-1420	71	27	two	two	NUM
dti-1420	71	28	patients	patient	NOUN
dti-1420	71	29	were	be	AUX
dti-1420	71	30	radiographically	radiographically	ADV
dti-1420	71	31	found	find	VERB
dti-1420	71	32	with	with	ADP
dti-1420	71	33	acute	acute	ADJ
dti-1420	71	34	interstitial	interstitial	ADJ
dti-1420	71	35	pneumonia	pneumonia	NOUN
dti-1420	71	36	/	/	SYM
dti-1420	71	37	acute	acute	ADJ
dti-1420	71	38	respiratory	respiratory	ADJ
dti-1420	71	39	distress	distress	NOUN
dti-1420	71	40	syndrome	syndrome	NOUN
dti-1420	71	41	,	,	PUNCT
dti-1420	71	42	and	and	CCONJ
dti-1420	71	43	one	one	NUM
dti-1420	71	44	patient	patient	NOUN
dti-1420	71	45	was	be	AUX
dti-1420	71	46	with	with	ADP
dti-1420	71	47	nonspecific	nonspecific	ADJ
dti-1420	71	48	interstitial	interstitial	ADJ
dti-1420	71	49	pneumonia	pneumonia	NOUN
dti-1420	71	50	.	.	PUNCT
dti-1420	72	1	two	two	NUM
dti-1420	72	2	of	of	ADP
dti-1420	72	3	these	these	DET
dti-1420	72	4	patients	patient	NOUN
dti-1420	72	5	required	require	VERB
dti-1420	72	6	admission	admission	NOUN
dti-1420	72	7	in	in	ADP
dti-1420	72	8	the	the	DET
dti-1420	72	9	intensive	intensive	ADJ
dti-1420	72	10	care	care	NOUN
dti-1420	72	11	unit	unit	NOUN
dti-1420	72	12	,	,	PUNCT
dti-1420	72	13	and	and	CCONJ
dti-1420	72	14	one	one	NUM
dti-1420	72	15	succumbed	succumb	VERB
dti-1420	72	16	four	four	NUM
dti-1420	72	17	weeks	week	NOUN
dti-1420	72	18	after	after	ADP
dti-1420	72	19	diagnosis	diagnosis	NOUN
dti-1420	72	20	of	of	ADP
dti-1420	72	21	pneumonitis	pneumonitis	NOUN
dti-1420	72	22	.	.	PUNCT
dti-1420	73	1	computed	compute	VERB
dti-1420	73	2	tomography	tomography	NOUN
dti-1420	73	3	findings	finding	NOUN
dti-1420	73	4	differed	differ	VERB
dti-1420	73	5	from	from	ADP
dti-1420	73	6	cop	cop	NOUN
dti-1420	73	7	,	,	PUNCT
dti-1420	73	8	and	and	CCONJ
dti-1420	73	9	bal	bal	ADJ
dti-1420	73	10	or	or	CCONJ
dti-1420	73	11	transbronchial	transbronchial	ADJ
dti-1420	73	12	biopsy	biopsy	NOUN
dti-1420	73	13	was	be	AUX
dti-1420	73	14	not	not	PART
dti-1420	73	15	performed	perform	VERB
dti-1420	73	16	in	in	ADP
dti-1420	73	17	these	these	DET
dti-1420	73	18	patients	patient	NOUN
dti-1420	73	19	.	.	PUNCT
dti-1420	74	1	another	another	DET
dti-1420	74	2	report	report	NOUN
dti-1420	74	3	involving	involve	VERB
dti-1420	74	4	a	a	DET
dti-1420	74	5	patient	patient	NOUN
dti-1420	74	6	treated	treat	VERB
dti-1420	74	7	with	with	ADP
dti-1420	74	8	nivolumab	nivolumab	NOUN
dti-1420	74	9	described	describe	VERB
dti-1420	74	10	an	an	DET
dti-1420	74	11	op	op	NOUN
dti-1420	74	12	diagnosed	diagnose	VERB
dti-1420	74	13	both	both	CCONJ
dti-1420	74	14	radiographically	radiographically	ADV
dti-1420	74	15	and	and	CCONJ
dti-1420	74	16	pathologically.19	pathologically.19	NOUN
dti-1420	74	17	similar	similar	ADJ
dti-1420	74	18	to	to	ADP
dti-1420	74	19	our	our	PRON
dti-1420	74	20	case	case	NOUN
dti-1420	74	21	,	,	PUNCT
dti-1420	74	22	ct	ct	NUM
dti-1420	74	23	of	of	ADP
dti-1420	74	24	the	the	DET
dti-1420	74	25	chest	chest	NOUN
dti-1420	74	26	showed	show	VERB
dti-1420	74	27	the	the	DET
dti-1420	74	28	typical	typical	ADJ
dti-1420	74	29	reversed	reversed	ADJ
dti-1420	74	30	halo	halo	NOUN
dti-1420	74	31	sign	sign	NOUN
dti-1420	74	32	and	and	CCONJ
dti-1420	74	33	had	have	VERB
dti-1420	74	34	a	a	DET
dti-1420	74	35	favorable	favorable	ADJ
dti-1420	74	36	response	response	NOUN
dti-1420	74	37	to	to	ADP
dti-1420	74	38	corticosteroid	corticosteroid	ADJ
dti-1420	74	39	therapy	therapy	NOUN
dti-1420	74	40	.	.	PUNCT
dti-1420	75	1	with	with	ADP
dti-1420	75	2	novel	novel	ADJ
dti-1420	75	3	immunotherapies	immunotherapy	NOUN
dti-1420	75	4	,	,	PUNCT
dti-1420	75	5	the	the	DET
dti-1420	75	6	incidence	incidence	NOUN
dti-1420	75	7	of	of	ADP
dti-1420	75	8	autoimmune	autoimmune	ADJ
dti-1420	75	9	phenomena	phenomenon	NOUN
dti-1420	75	10	is	be	AUX
dti-1420	75	11	rising	rise	VERB
dti-1420	75	12	;	;	PUNCT
dti-1420	75	13	therefore	therefore	ADV
dti-1420	75	14	,	,	PUNCT
dti-1420	75	15	it	it	PRON
dti-1420	75	16	is	be	AUX
dti-1420	75	17	important	important	ADJ
dti-1420	75	18	to	to	PART
dti-1420	75	19	recognize	recognize	VERB
dti-1420	75	20	an	an	DET
dti-1420	75	21	op	op	NOUN
dti-1420	75	22	early	early	ADV
dti-1420	75	23	in	in	ADP
dti-1420	75	24	any	any	DET
dti-1420	75	25	patient	patient	NOUN
dti-1420	75	26	receiving	receive	VERB
dti-1420	75	27	anti	anti	NOUN
dti-1420	75	28	-	-	NOUN
dti-1420	75	29	pd-1	pd-1	ADJ
dti-1420	75	30	and	and	CCONJ
dti-1420	75	31	presenting	present	VERB
dti-1420	75	32	with	with	ADP
dti-1420	75	33	symptoms	symptom	NOUN
dti-1420	75	34	of	of	ADP
dti-1420	75	35	new	new	ADJ
dti-1420	75	36	cough	cough	NOUN
dti-1420	75	37	or	or	CCONJ
dti-1420	75	38	shortness	shortness	NOUN
dti-1420	75	39	of	of	ADP
dti-1420	75	40	breath	breath	NOUN
dti-1420	75	41	.	.	PUNCT
dti-1420	76	1	the	the	DET
dti-1420	76	2	diagnosis	diagnosis	NOUN
dti-1420	76	3	needs	need	VERB
dti-1420	76	4	to	to	PART
dti-1420	76	5	be	be	AUX
dti-1420	76	6	supported	support	VERB
dti-1420	76	7	by	by	ADP
dti-1420	76	8	imaging	imaging	NOUN
dti-1420	76	9	and	and	CCONJ
dti-1420	76	10	cytological	cytological	ADJ
dti-1420	76	11	investigations	investigation	NOUN
dti-1420	76	12	.	.	PUNCT
dti-1420	77	1	although	although	SCONJ
dti-1420	77	2	the	the	DET
dti-1420	77	3	exact	exact	ADJ
dti-1420	77	4	causative	causative	ADJ
dti-1420	77	5	mechanism	mechanism	NOUN
dti-1420	77	6	of	of	ADP
dti-1420	77	7	op	op	NOUN
dti-1420	77	8	by	by	ADP
dti-1420	77	9	anti	anti	ADJ
dti-1420	77	10	-	-	ADJ
dti-1420	77	11	pd-1	pd-1	ADJ
dti-1420	77	12	mab	mab	NOUN
dti-1420	77	13	therapy	therapy	NOUN
dti-1420	77	14	can	can	AUX
dti-1420	77	15	not	not	PART
dti-1420	77	16	be	be	AUX
dti-1420	77	17	established	establish	VERB
dti-1420	77	18	as	as	ADP
dti-1420	77	19	yet	yet	ADV
dti-1420	77	20	,	,	PUNCT
dti-1420	77	21	a	a	DET
dti-1420	77	22	t	t	NOUN
dti-1420	77	23	-	-	PUNCT
dti-1420	77	24	cell	cell	NOUN
dti-1420	77	25	or	or	CCONJ
dti-1420	77	26	macrophage	macrophage	ADV
dti-1420	77	27	-	-	PUNCT
dti-1420	77	28	driven	drive	VERB
dti-1420	77	29	effect	effect	NOUN
dti-1420	77	30	is	be	AUX
dti-1420	77	31	the	the	DET
dti-1420	77	32	most	most	ADV
dti-1420	77	33	plausible	plausible	ADJ
dti-1420	77	34	explanation	explanation	NOUN
dti-1420	77	35	,	,	PUNCT
dti-1420	77	36	and	and	CCONJ
dti-1420	77	37	further	further	ADJ
dti-1420	77	38	studies	study	NOUN
dti-1420	77	39	are	be	AUX
dti-1420	77	40	warranted	warrant	VERB
dti-1420	77	41	to	to	PART
dti-1420	77	42	define	define	VERB
dti-1420	77	43	the	the	DET
dti-1420	77	44	pathogenic	pathogenic	ADJ
dti-1420	77	45	mechanism	mechanism	NOUN
dti-1420	77	46	underlying	underlie	VERB
dti-1420	77	47	this	this	DET
dti-1420	77	48	possibly	possibly	ADV
dti-1420	77	49	lethal	lethal	ADJ
dti-1420	77	50	side	side	NOUN
dti-1420	77	51	effect	effect	NOUN
dti-1420	77	52	.	.	PUNCT
dti-1420	78	1	acknowledgment	acknowledgment	NOUN
dti-1420	78	2	the	the	DET
dti-1420	78	3	authors	author	NOUN
dti-1420	78	4	are	be	AUX
dti-1420	78	5	obliged	oblige	VERB
dti-1420	78	6	to	to	AUX
dti-1420	78	7	professor	professor	NOUN
dti-1420	78	8	dimitrios	dimitrio	NOUN
dti-1420	78	9	boumpas	boumpas	VERB
dti-1420	78	10	for	for	ADP
dti-1420	78	11	critical	critical	ADJ
dti-1420	78	12	revision	revision	NOUN
dti-1420	78	13	of	of	ADP
dti-1420	78	14	the	the	DET
dti-1420	78	15	manuscript	manuscript	NOUN
dti-1420	78	16	.	.	PUNCT
dti-1420	79	1	author	author	NOUN
dti-1420	79	2	contributions	contribution	NOUN
dti-1420	79	3	conceived	conceive	VERB
dti-1420	79	4	and	and	CCONJ
dti-1420	79	5	designed	design	VERB
dti-1420	79	6	the	the	DET
dti-1420	79	7	experiments	experiment	NOUN
dti-1420	79	8	:	:	PUNCT
dti-1420	79	9	ak	ak	PROPN
dti-1420	79	10	.	.	PROPN
dti-1420	79	11	analyzed	analyze	VERB
dti-1420	79	12	the	the	DET
dti-1420	79	13	data	datum	NOUN
dti-1420	79	14	:	:	PUNCT
dti-1420	79	15	ms	ms	PROPN
dti-1420	79	16	.	.	PROPN
dti-1420	79	17	wrote	write	VERB
dti-1420	79	18	the	the	DET
dti-1420	79	19	first	first	ADJ
dti-1420	79	20	draft	draft	NOUN
dti-1420	79	21	of	of	ADP
dti-1420	79	22	the	the	DET
dti-1420	79	23	manuscript	manuscript	NOUN
dti-1420	79	24	:	:	PUNCT
dti-1420	79	25	pf	pf	PROPN
dti-1420	79	26	.	.	PROPN
dti-1420	79	27	contributed	contribute	VERB
dti-1420	79	28	to	to	ADP
dti-1420	79	29	the	the	DET
dti-1420	79	30	writing	writing	NOUN
dti-1420	79	31	of	of	ADP
dti-1420	79	32	the	the	DET
dti-1420	79	33	manuscript	manuscript	NOUN
dti-1420	79	34	:	:	PUNCT
dti-1420	79	35	pf	pf	PROPN
dti-1420	79	36	,	,	PUNCT
dti-1420	79	37	ms	ms	PROPN
dti-1420	79	38	,	,	PUNCT
dti-1420	79	39	mt	mt	PROPN
dti-1420	79	40	,	,	PUNCT
dti-1420	79	41	ck	ck	PROPN
dti-1420	79	42	,	,	PUNCT
dti-1420	79	43	sl	sl	PROPN
dti-1420	79	44	,	,	PUNCT
dti-1420	79	45	ak	ak	PROPN
dti-1420	79	46	.	.	PROPN
dti-1420	79	47	agree	agree	VERB
dti-1420	79	48	with	with	ADP
dti-1420	79	49	manuscript	manuscript	NOUN
dti-1420	79	50	results	result	NOUN
dti-1420	79	51	and	and	CCONJ
dti-1420	79	52	conclusions	conclusion	NOUN
dti-1420	79	53	:	:	PUNCT
dti-1420	79	54	pf	pf	PROPN
dti-1420	79	55	,	,	PUNCT
dti-1420	79	56	ms	ms	PROPN
dti-1420	79	57	,	,	PUNCT
dti-1420	79	58	mt	mt	PROPN
dti-1420	79	59	,	,	PUNCT
dti-1420	79	60	ck	ck	PROPN
dti-1420	79	61	,	,	PUNCT
dti-1420	79	62	sl	sl	PROPN
dti-1420	79	63	,	,	PUNCT
dti-1420	79	64	ak	ak	PROPN
dti-1420	79	65	.	.	PROPN
dti-1420	79	66	jointly	jointly	ADV
dti-1420	79	67	developed	develop	VERB
dti-1420	79	68	the	the	DET
dti-1420	79	69	structure	structure	NOUN
dti-1420	79	70	and	and	CCONJ
dti-1420	79	71	arguments	argument	NOUN
dti-1420	79	72	for	for	ADP
dti-1420	79	73	the	the	DET
dti-1420	79	74	paper	paper	NOUN
dti-1420	79	75	:	:	PUNCT
dti-1420	79	76	pf	pf	PROPN
dti-1420	79	77	,	,	PUNCT
dti-1420	79	78	ms	ms	PROPN
dti-1420	79	79	,	,	PUNCT
dti-1420	79	80	mt	mt	PROPN
dti-1420	79	81	,	,	PUNCT
dti-1420	79	82	ck	ck	PROPN
dti-1420	79	83	,	,	PUNCT
dti-1420	79	84	sl	sl	PROPN
dti-1420	79	85	,	,	PUNCT
dti-1420	79	86	ak	ak	PROPN
dti-1420	79	87	.	.	PROPN
dti-1420	79	88	made	make	VERB
dti-1420	79	89	critical	critical	ADJ
dti-1420	79	90	revisions	revision	NOUN
dti-1420	79	91	and	and	CCONJ
dti-1420	79	92	approved	approve	VERB
dti-1420	79	93	final	final	ADJ
dti-1420	79	94	version	version	NOUN
dti-1420	79	95	:	:	PUNCT
dti-1420	80	1	pf	pf	PROPN
dti-1420	80	2	,	,	PUNCT
dti-1420	80	3	ms	ms	PROPN
dti-1420	80	4	,	,	PUNCT
dti-1420	80	5	mt	mt	PROPN
dti-1420	80	6	,	,	PUNCT
dti-1420	80	7	ck	ck	PROPN
dti-1420	80	8	,	,	PUNCT
dti-1420	80	9	sl	sl	PROPN
dti-1420	80	10	,	,	PUNCT
dti-1420	80	11	ak	ak	PROPN
dti-1420	80	12	.	.	PROPN
dti-1420	81	1	all	all	DET
dti-1420	81	2	authors	author	NOUN
dti-1420	81	3	reviewed	review	VERB
dti-1420	81	4	and	and	CCONJ
dti-1420	81	5	approved	approve	VERB
dti-1420	81	6	of	of	ADP
dti-1420	81	7	the	the	DET
dti-1420	81	8	final	final	ADJ
dti-1420	81	9	manuscript	manuscript	NOUN
dti-1420	81	10	.	.	PUNCT
dti-1420	82	1	references	reference	NOUN
dti-1420	82	2	1	1	NUM
dti-1420	82	3	.	.	PUNCT
dti-1420	83	1	postow	postow	PROPN
dti-1420	83	2	ma	ma	PROPN
dti-1420	83	3	,	,	PUNCT
dti-1420	83	4	callahan	callahan	PROPN
dti-1420	83	5	mk	mk	PROPN
dti-1420	83	6	,	,	PUNCT
dti-1420	83	7	wolchok	wolchok	PROPN
dti-1420	83	8	jd	jd	PROPN
dti-1420	83	9	.	.	PROPN
dti-1420	83	10	immune	immune	ADJ
dti-1420	83	11	checkpoint	checkpoint	NOUN
dti-1420	83	12	blockade	blockade	NOUN
dti-1420	83	13	in	in	ADP
dti-1420	83	14	cancer	cancer	NOUN
dti-1420	83	15	therapy	therapy	NOUN
dti-1420	83	16	.	.	PUNCT
dti-1420	84	1	j	j	PROPN
dti-1420	84	2	clin	clin	PROPN
dti-1420	84	3	oncol	oncol	PROPN
dti-1420	84	4	.	.	PUNCT
dti-1420	85	1	2015;33(17):1974–1982	2015;33(17):1974–1982	NUM
dti-1420	85	2	.	.	NOUN
dti-1420	85	3	2	2	NUM
dti-1420	85	4	.	.	X
dti-1420	85	5	national	national	PROPN
dti-1420	85	6	cancer	cancer	PROPN
dti-1420	85	7	institute	institute	PROPN
dti-1420	85	8	,	,	PUNCT
dti-1420	85	9	national	national	PROPN
dti-1420	85	10	institutes	institutes	PROPN
dti-1420	85	11	of	of	ADP
dti-1420	85	12	health	health	PROPN
dti-1420	85	13	,	,	PUNCT
dti-1420	85	14	u.s	u.s	PROPN
dti-1420	85	15	.	.	PROPN
dti-1420	85	16	department	department	PROPN
dti-1420	85	17	of	of	ADP
dti-1420	85	18	health	health	PROPN
dti-1420	85	19	and	and	CCONJ
dti-1420	85	20	human	human	ADJ
dti-1420	85	21	services	service	NOUN
dti-1420	85	22	.	.	PUNCT
dti-1420	86	1	common	common	ADJ
dti-1420	86	2	terminology	terminology	NOUN
dti-1420	86	3	criteria	criterion	NOUN
dti-1420	86	4	for	for	ADP
dti-1420	86	5	adverse	adverse	ADJ
dti-1420	86	6	events	event	NOUN
dti-1420	86	7	(	(	PUNCT
dti-1420	86	8	ctcae	ctcae	NOUN
dti-1420	86	9	)	)	PUNCT
dti-1420	86	10	.	.	PUNCT
dti-1420	87	1	version	version	NOUN
dti-1420	87	2	4.0	4.0	NUM
dti-1420	87	3	.	.	PUNCT
dti-1420	88	1	bethesda	bethesda	PROPN
dti-1420	88	2	,	,	PUNCT
dti-1420	88	3	md	md	PROPN
dti-1420	88	4	:	:	PUNCT
dti-1420	88	5	nih	nih	PROPN
dti-1420	88	6	.	.	PROPN
dti-1420	88	7	published	publish	VERB
dti-1420	88	8	:	:	PUNCT
dti-1420	88	9	may	may	AUX
dti-1420	88	10	28	28	NUM
dti-1420	88	11	,	,	PUNCT
dti-1420	88	12	2009	2009	NUM
dti-1420	88	13	(	(	PUNCT
dti-1420	88	14	v4.03	v4.03	NOUN
dti-1420	88	15	:	:	PUNCT
dti-1420	88	16	june	june	PROPN
dti-1420	88	17	14	14	NUM
dti-1420	88	18	,	,	PUNCT
dti-1420	88	19	2010	2010	NUM
dti-1420	88	20	)	)	PUNCT
dti-1420	88	21	.	.	PUNCT
dti-1420	89	1	nih	nih	PROPN
dti-1420	89	2	publication	publication	PROPN
dti-1420	89	3	no	no	INTJ
dti-1420	89	4	.	.	PROPN
dti-1420	89	5	09	09	NUM
dti-1420	89	6	-	-	SYM
dti-1420	89	7	5410	5410	NUM
dti-1420	89	8	.	.	PUNCT
dti-1420	90	1	revised	revise	VERB
dti-1420	90	2	june	june	PROPN
dti-1420	90	3	2010	2010	NUM
dti-1420	90	4	.	.	PUNCT
dti-1420	91	1	3	3	X
dti-1420	91	2	.	.	X
dti-1420	92	1	mcdermott	mcdermott	PROPN
dti-1420	92	2	d	d	PROPN
dti-1420	92	3	,	,	PUNCT
dti-1420	92	4	lebbe	lebbe	NOUN
dti-1420	92	5	c	c	AUX
dti-1420	92	6	,	,	PUNCT
dti-1420	92	7	hodi	hodi	PROPN
dti-1420	92	8	fs	fs	PROPN
dti-1420	92	9	,	,	PUNCT
dti-1420	92	10	et	et	PROPN
dti-1420	92	11	al	al	PROPN
dti-1420	92	12	.	.	PUNCT
dti-1420	92	13	durable	durable	ADJ
dti-1420	92	14	benefit	benefit	NOUN
dti-1420	92	15	and	and	CCONJ
dti-1420	92	16	the	the	DET
dti-1420	92	17	potential	potential	NOUN
dti-1420	92	18	for	for	ADP
dti-1420	92	19	long	long	ADJ
dti-1420	92	20	-	-	PUNCT
dti-1420	92	21	term	term	NOUN
dti-1420	92	22	survival	survival	NOUN
dti-1420	92	23	with	with	ADP
dti-1420	92	24	immunotherapy	immunotherapy	NOUN
dti-1420	92	25	in	in	ADP
dti-1420	92	26	advanced	advanced	ADJ
dti-1420	92	27	melanoma	melanoma	NOUN
dti-1420	92	28	.	.	PUNCT
dti-1420	93	1	cancer	cancer	NOUN
dti-1420	93	2	treat	treat	PROPN
dti-1420	93	3	rev	rev	VERB
dti-1420	93	4	.	.	PUNCT
dti-1420	94	1	2014;40:1056–1064	2014;40:1056–1064	NUM
dti-1420	94	2	.	.	NOUN
dti-1420	95	1	4	4	NUM
dti-1420	95	2	.	.	X
dti-1420	95	3	eggermont	eggermont	PROPN
dti-1420	95	4	am	am	PROPN
dti-1420	95	5	,	,	PUNCT
dti-1420	95	6	maio	maio	PROPN
dti-1420	95	7	m	m	PROPN
dti-1420	95	8	,	,	PUNCT
dti-1420	95	9	robert	robert	PROPN
dti-1420	95	10	c.	c.	PROPN
dti-1420	95	11	immune	immune	PROPN
dti-1420	95	12	checkpoint	checkpoint	NOUN
dti-1420	95	13	inhibitors	inhibitor	NOUN
dti-1420	95	14	in	in	ADP
dti-1420	95	15	melanoma	melanoma	NOUN
dti-1420	95	16	provide	provide	VERB
dti-1420	95	17	the	the	DET
dti-1420	95	18	cornerstones	cornerstone	NOUN
dti-1420	95	19	for	for	ADP
dti-1420	95	20	curative	curative	ADJ
dti-1420	95	21	therapies	therapy	NOUN
dti-1420	95	22	.	.	PUNCT
dti-1420	96	1	semin	semin	PROPN
dti-1420	96	2	oncol	oncol	PROPN
dti-1420	96	3	.	.	PUNCT
dti-1420	97	1	2015;42:429–435	2015;42:429–435	NOUN
dti-1420	97	2	.	.	NOUN
dti-1420	98	1	5	5	NUM
dti-1420	98	2	.	.	PUNCT
dti-1420	98	3	robert	robert	PROPN
dti-1420	98	4	c	c	PROPN
dti-1420	98	5	,	,	PUNCT
dti-1420	98	6	schachter	schachter	PROPN
dti-1420	98	7	j	j	PROPN
dti-1420	98	8	,	,	PUNCT
dti-1420	98	9	long	long	ADV
dti-1420	98	10	gv	gv	ADP
dti-1420	98	11	,	,	PUNCT
dti-1420	98	12	et	et	PROPN
dti-1420	98	13	al	al	PROPN
dti-1420	98	14	.	.	PROPN
dti-1420	98	15	pembrolizumab	pembrolizumab	NOUN
dti-1420	98	16	versus	versus	ADP
dti-1420	98	17	ipilimumab	ipilimumab	NOUN
dti-1420	98	18	in	in	ADP
dti-1420	98	19	advanced	advanced	ADJ
dti-1420	98	20	melanoma	melanoma	NOUN
dti-1420	98	21	.	.	PUNCT
dti-1420	99	1	n	n	PRON
dti-1420	99	2	engl	engl	PROPN
dti-1420	99	3	j	j	PROPN
dti-1420	99	4	med	med	PROPN
dti-1420	99	5	.	.	PUNCT
dti-1420	100	1	2015;372:2521–2532	2015;372:2521–2532	X
dti-1420	100	2	.	.	NOUN
dti-1420	100	3	6	6	NUM
dti-1420	100	4	.	.	X
dti-1420	100	5	thibult	thibult	ADJ
dti-1420	100	6	ml	ml	NOUN
dti-1420	100	7	,	,	PUNCT
dti-1420	100	8	mamessier	mamessier	NOUN
dti-1420	100	9	e	e	NOUN
dti-1420	100	10	,	,	PUNCT
dti-1420	100	11	gertner	gertner	NOUN
dti-1420	100	12	-	-	PUNCT
dti-1420	100	13	dardenne	dardenne	NOUN
dti-1420	100	14	j	j	PROPN
dti-1420	100	15	,	,	PUNCT
dti-1420	100	16	et	et	PROPN
dti-1420	100	17	al	al	PROPN
dti-1420	100	18	.	.	PROPN
dti-1420	100	19	pd-1	pd-1	PROPN
dti-1420	100	20	is	be	AUX
dti-1420	100	21	a	a	DET
dti-1420	100	22	novel	novel	ADJ
dti-1420	100	23	regulator	regulator	NOUN
dti-1420	100	24	of	of	ADP
dti-1420	100	25	human	human	PROPN
dti-1420	100	26	b	b	PROPN
dti-1420	100	27	-	-	PUNCT
dti-1420	100	28	cell	cell	NOUN
dti-1420	100	29	activation	activation	NOUN
dti-1420	100	30	.	.	PUNCT
dti-1420	101	1	int	int	NOUN
dti-1420	101	2	immunol	immunol	NOUN
dti-1420	101	3	.	.	PUNCT
dti-1420	102	1	2013;25:129–137	2013;25:129–137	NUM
dti-1420	102	2	.	.	PUNCT
dti-1420	103	1	7	7	X
dti-1420	103	2	.	.	X
dti-1420	103	3	jin	jin	PROPN
dti-1420	103	4	ht	ht	PROPN
dti-1420	103	5	,	,	PUNCT
dti-1420	103	6	ahmed	ahmed	PROPN
dti-1420	103	7	r	r	PROPN
dti-1420	103	8	,	,	PUNCT
dti-1420	103	9	okazaki	okazaki	PROPN
dti-1420	103	10	t.	t.	ADJ
dti-1420	103	11	role	role	NOUN
dti-1420	103	12	of	of	ADP
dti-1420	103	13	pd-1	pd-1	VERB
dti-1420	103	14	in	in	ADP
dti-1420	103	15	regulating	regulate	VERB
dti-1420	103	16	t	t	NOUN
dti-1420	103	17	-	-	PUNCT
dti-1420	103	18	cell	cell	NOUN
dti-1420	103	19	immunity	immunity	NOUN
dti-1420	103	20	.	.	PUNCT
dti-1420	104	1	curr	curr	PROPN
dti-1420	104	2	top	top	PROPN
dti-1420	104	3	microbiol	microbiol	PROPN
dti-1420	104	4	immunol	immunol	NOUN
dti-1420	104	5	.	.	PUNCT
dti-1420	105	1	2011;350:17–37	2011;350:17–37	NUM
dti-1420	105	2	.	.	NOUN
dti-1420	105	3	8	8	NUM
dti-1420	105	4	.	.	PUNCT
dti-1420	106	1	huang	huang	PROPN
dti-1420	106	2	x	x	PROPN
dti-1420	106	3	,	,	PUNCT
dti-1420	106	4	venet	venet	PROPN
dti-1420	106	5	f	f	X
dti-1420	106	6	,	,	PUNCT
dti-1420	106	7	wang	wang	PROPN
dti-1420	106	8	yl	yl	PROPN
dti-1420	106	9	,	,	PUNCT
dti-1420	106	10	et	et	PROPN
dti-1420	106	11	al	al	PROPN
dti-1420	106	12	.	.	PROPN
dti-1420	106	13	pd-1	pd-1	ADP
dti-1420	106	14	expression	expression	NOUN
dti-1420	106	15	by	by	ADP
dti-1420	106	16	macrophages	macrophage	NOUN
dti-1420	106	17	plays	play	VERB
dti-1420	106	18	a	a	DET
dti-1420	106	19	pathologic	pathologic	ADJ
dti-1420	106	20	role	role	NOUN
dti-1420	106	21	in	in	ADP
dti-1420	106	22	altering	alter	VERB
dti-1420	106	23	microbial	microbial	ADJ
dti-1420	106	24	clearance	clearance	NOUN
dti-1420	106	25	and	and	CCONJ
dti-1420	106	26	the	the	DET
dti-1420	106	27	innate	innate	ADJ
dti-1420	106	28	inflammatory	inflammatory	ADJ
dti-1420	106	29	response	response	NOUN
dti-1420	106	30	to	to	ADP
dti-1420	106	31	sepsis	sepsis	NOUN
dti-1420	106	32	.	.	PUNCT
dti-1420	107	1	proc	proc	PROPN
dti-1420	107	2	natl	natl	PROPN
dti-1420	107	3	acad	acad	PROPN
dti-1420	107	4	sci	sci	PROPN
dti-1420	107	5	u	u	PROPN
dti-1420	107	6	s	s	NOUN
dti-1420	107	7	a.	a.	NOUN
dti-1420	107	8	2009;106:6303–6308	2009;106:6303–6308	NUM
dti-1420	107	9	.	.	PUNCT
dti-1420	108	1	9	9	NUM
dti-1420	108	2	.	.	X
dti-1420	108	3	wu	wu	PROPN
dti-1420	109	1	p	p	PROPN
dti-1420	109	2	,	,	PUNCT
dti-1420	109	3	wu	wu	PROPN
dti-1420	109	4	d	d	PROPN
dti-1420	109	5	,	,	PUNCT
dti-1420	109	6	li	li	PROPN
dti-1420	109	7	l	l	PROPN
dti-1420	109	8	,	,	PUNCT
dti-1420	109	9	chai	chai	NOUN
dti-1420	109	10	y	y	PROPN
dti-1420	109	11	,	,	PUNCT
dti-1420	109	12	huang	huang	PROPN
dti-1420	109	13	j.	j.	PROPN
dti-1420	109	14	pd	pd	PROPN
dti-1420	109	15	-	-	PROPN
dti-1420	109	16	l1	l1	PROPN
dti-1420	109	17	and	and	CCONJ
dti-1420	109	18	survival	survival	NOUN
dti-1420	109	19	in	in	ADP
dti-1420	109	20	solid	solid	ADJ
dti-1420	109	21	tumors	tumor	NOUN
dti-1420	109	22	:	:	PUNCT
dti-1420	109	23	a	a	DET
dti-1420	109	24	 	 	SPACE
dti-1420	109	25	meta	meta	NOUN
dti-1420	109	26	-	-	PUNCT
dti-1420	109	27	analysis	analysis	NOUN
dti-1420	109	28	.	.	PUNCT
dti-1420	110	1	plos	plos	PROPN
dti-1420	110	2	one	one	NUM
dti-1420	110	3	.	.	PUNCT
dti-1420	111	1	2015;10	2015;10	NUM
dti-1420	111	2	:	:	PUNCT
dti-1420	111	3	e0131403	e0131403	NOUN
dti-1420	111	4	.	.	PUNCT
dti-1420	112	1	10	10	NUM
dti-1420	112	2	.	.	PUNCT
dti-1420	113	1	pardoll	pardoll	PROPN
dti-1420	113	2	dm	dm	PROPN
dti-1420	113	3	.	.	PUNCT
dti-1420	114	1	the	the	DET
dti-1420	114	2	blockade	blockade	NOUN
dti-1420	114	3	of	of	ADP
dti-1420	114	4	immune	immune	ADJ
dti-1420	114	5	checkpoints	checkpoint	NOUN
dti-1420	114	6	in	in	ADP
dti-1420	114	7	cancer	cancer	NOUN
dti-1420	114	8	immunotherapy	immunotherapy	NOUN
dti-1420	114	9	.	.	PUNCT
dti-1420	115	1	nat	nat	PROPN
dti-1420	115	2	rev	rev	PROPN
dti-1420	115	3	cancer	cancer	NOUN
dti-1420	115	4	.	.	PUNCT
dti-1420	116	1	2012;12:252–264	2012;12:252–264	NOUN
dti-1420	116	2	.	.	PUNCT
dti-1420	117	1	11	11	NUM
dti-1420	117	2	.	.	PUNCT
dti-1420	117	3	weiner	weiner	NOUN
dti-1420	117	4	gj	gj	AUX
dti-1420	117	5	.	.	PUNCT
dti-1420	117	6	rituximab	rituximab	NOUN
dti-1420	117	7	:	:	PUNCT
dti-1420	117	8	mechanism	mechanism	NOUN
dti-1420	117	9	of	of	ADP
dti-1420	117	10	action	action	NOUN
dti-1420	117	11	.	.	PUNCT
dti-1420	118	1	semin	semin	PROPN
dti-1420	118	2	hematol	hematol	PROPN
dti-1420	118	3	.	.	PUNCT
dti-1420	119	1	2010;47:115–123	2010;47:115–123	NOUN
dti-1420	119	2	.	.	PUNCT
dti-1420	120	1	http://www.la-press.com	http://www.la-press.com	X
dti-1420	120	2	http://www.la-press.com/drug-target-insights-journal-j23	http://www.la-press.com/drug-target-insights-journal-j23	AUX
dti-1420	120	3	fragkou	fragkou	PROPN
dti-1420	120	4	et	et	NOUN
dti-1420	120	5	al	al	PROPN
dti-1420	120	6	12	12	NUM
dti-1420	120	7	drug	drug	NOUN
dti-1420	120	8	target	target	NOUN
dti-1420	120	9	insights	insight	NOUN
dti-1420	120	10	2016:10	2016:10	NUM
dti-1420	120	11	12	12	NUM
dti-1420	120	12	.	.	PUNCT
dti-1420	121	1	hamid	hamid	PROPN
dti-1420	121	2	o	o	PROPN
dti-1420	121	3	,	,	PUNCT
dti-1420	121	4	robert	robert	PROPN
dti-1420	121	5	c	c	PROPN
dti-1420	121	6	,	,	PUNCT
dti-1420	121	7	daud	daud	PROPN
dti-1420	121	8	a	a	X
dti-1420	121	9	,	,	PUNCT
dti-1420	121	10	et	et	PROPN
dti-1420	121	11	al	al	PROPN
dti-1420	121	12	.	.	PROPN
dti-1420	121	13	safety	safety	PROPN
dti-1420	121	14	and	and	CCONJ
dti-1420	121	15	tumor	tumor	NOUN
dti-1420	121	16	responses	response	NOUN
dti-1420	121	17	with	with	ADP
dti-1420	121	18	lambrolizumab	lambrolizumab	PROPN
dti-1420	121	19	(	(	PUNCT
dti-1420	121	20	anti	anti	ADJ
dti-1420	121	21	-	-	ADJ
dti-1420	121	22	pd-1	pd-1	ADJ
dti-1420	121	23	)	)	PUNCT
dti-1420	121	24	in	in	ADP
dti-1420	121	25	melanoma	melanoma	NOUN
dti-1420	121	26	.	.	PUNCT
dti-1420	122	1	n	n	PRON
dti-1420	122	2	engl	engl	PROPN
dti-1420	122	3	j	j	PROPN
dti-1420	122	4	med	med	PROPN
dti-1420	122	5	.	.	PUNCT
dti-1420	123	1	2013;369:134–144	2013;369:134–144	NUM
dti-1420	123	2	.	.	PUNCT
dti-1420	124	1	13	13	NUM
dti-1420	124	2	.	.	X
dti-1420	125	1	travis	travis	PROPN
dti-1420	125	2	wd	wd	PROPN
dti-1420	125	3	,	,	PUNCT
dti-1420	125	4	costabel	costabel	NOUN
dti-1420	125	5	u	u	NOUN
dti-1420	125	6	,	,	PUNCT
dti-1420	125	7	hansell	hansell	PROPN
dti-1420	125	8	dm	dm	PROPN
dti-1420	125	9	,	,	PUNCT
dti-1420	125	10	et	et	PROPN
dti-1420	125	11	al	al	PROPN
dti-1420	125	12	.	.	PUNCT
dti-1420	126	1	an	an	DET
dti-1420	126	2	official	official	ADJ
dti-1420	126	3	american	american	ADJ
dti-1420	126	4	thoracic	thoracic	NOUN
dti-1420	126	5	society	society	PROPN
dti-1420	126	6	/	/	SYM
dti-1420	126	7	european	european	ADJ
dti-1420	126	8	respiratory	respiratory	ADJ
dti-1420	126	9	society	society	NOUN
dti-1420	126	10	statement	statement	NOUN
dti-1420	126	11	:	:	PUNCT
dti-1420	126	12	update	update	NOUN
dti-1420	126	13	of	of	ADP
dti-1420	126	14	the	the	DET
dti-1420	126	15	international	international	ADJ
dti-1420	126	16	multidisciplinary	multidisciplinary	ADJ
dti-1420	126	17	classification	classification	NOUN
dti-1420	126	18	of	of	ADP
dti-1420	126	19	the	the	DET
dti-1420	126	20	idiopathic	idiopathic	ADJ
dti-1420	126	21	interstitial	interstitial	ADJ
dti-1420	126	22	pneumonias	pneumonia	NOUN
dti-1420	126	23	.	.	PUNCT
dti-1420	127	1	am	be	AUX
dti-1420	127	2	j	j	NOUN
dti-1420	127	3	 	 	SPACE
dti-1420	127	4	respir	respir	VERB
dti-1420	127	5	crit	crit	PROPN
dti-1420	127	6	care	care	NOUN
dti-1420	127	7	med	me	VERB
dti-1420	127	8	.	.	PUNCT
dti-1420	127	9	2013;188:733–748	2013;188:733–748	NUM
dti-1420	127	10	.	.	PUNCT
dti-1420	128	1	14	14	NUM
dti-1420	128	2	.	.	PUNCT
dti-1420	129	1	barker	barker	PROPN
dti-1420	129	2	af	af	PROPN
dti-1420	129	3	,	,	PUNCT
dti-1420	129	4	bergeron	bergeron	PROPN
dti-1420	129	5	a	a	PROPN
dti-1420	129	6	,	,	PUNCT
dti-1420	129	7	rom	rom	PROPN
dti-1420	129	8	wn	wn	PROPN
dti-1420	129	9	,	,	PUNCT
dti-1420	129	10	et	et	PROPN
dti-1420	129	11	al	al	PROPN
dti-1420	129	12	.	.	PROPN
dti-1420	129	13	obliterative	obliterative	ADJ
dti-1420	129	14	bronchiolitis	bronchiolitis	NOUN
dti-1420	129	15	.	.	PUNCT
dti-1420	130	1	n	n	PROPN
dti-1420	130	2	engl	engl	PROPN
dti-1420	130	3	j	j	PROPN
dti-1420	130	4	 	 	SPACE
dti-1420	130	5	med	med	PROPN
dti-1420	130	6	.	.	PUNCT
dti-1420	131	1	2014;370:1820–1828	2014;370:1820–1828	X
dti-1420	131	2	.	.	X
dti-1420	131	3	15	15	NUM
dti-1420	131	4	.	.	PUNCT
dti-1420	131	5	cordier	cordier	PROPN
dti-1420	131	6	jf	jf	PROPN
dti-1420	131	7	.	.	PROPN
dti-1420	131	8	cryptogenic	cryptogenic	ADJ
dti-1420	131	9	organising	organising	NOUN
dti-1420	131	10	pneumonia	pneumonia	NOUN
dti-1420	131	11	.	.	PUNCT
dti-1420	132	1	eur	eur	PROPN
dti-1420	132	2	respir	respir	PROPN
dti-1420	132	3	j.	j.	PROPN
dti-1420	132	4	2006;28:422–446	2006;28:422–446	PROPN
dti-1420	132	5	.	.	PUNCT
dti-1420	133	1	16	16	NUM
dti-1420	133	2	.	.	PUNCT
dti-1420	134	1	nishimura	nishimura	PROPN
dti-1420	134	2	k	k	PROPN
dti-1420	134	3	,	,	PUNCT
dti-1420	134	4	itoh	itoh	PROPN
dti-1420	134	5	h.	h.	PROPN
dti-1420	134	6	high	high	ADJ
dti-1420	134	7	-	-	PUNCT
dti-1420	134	8	resolution	resolution	NOUN
dti-1420	134	9	computed	compute	VERB
dti-1420	134	10	tomographic	tomographic	ADJ
dti-1420	134	11	features	feature	NOUN
dti-1420	134	12	of	of	ADP
dti-1420	134	13	bronchiolitis	bronchiolitis	ADJ
dti-1420	134	14	obliterans	obliteran	NOUN
dti-1420	134	15	organizing	organize	VERB
dti-1420	134	16	pneumonia	pneumonia	NOUN
dti-1420	134	17	.	.	PUNCT
dti-1420	135	1	chest	chest	NOUN
dti-1420	135	2	.	.	PUNCT
dti-1420	136	1	1992;102:26s–31s	1992;102:26s–31s	NUM
dti-1420	136	2	.	.	NOUN
dti-1420	136	3	17	17	NUM
dti-1420	136	4	.	.	PUNCT
dti-1420	137	1	kim	kim	PROPN
dti-1420	137	2	km	km	PROPN
dti-1420	137	3	,	,	PUNCT
dti-1420	137	4	kim	kim	PROPN
dti-1420	137	5	hc	hc	PROPN
dti-1420	137	6	,	,	PUNCT
dti-1420	137	7	jeon	jeon	PROPN
dti-1420	137	8	kn	kn	PROPN
dti-1420	137	9	,	,	PUNCT
dti-1420	137	10	et	et	PROPN
dti-1420	137	11	al	al	PROPN
dti-1420	137	12	.	.	PROPN
dti-1420	137	13	rituximab	rituximab	NOUN
dti-1420	137	14	-	-	PUNCT
dti-1420	137	15	chop	chop	NOUN
dti-1420	137	16	induced	induce	VERB
dti-1420	137	17	interstitial	interstitial	ADJ
dti-1420	137	18	pneumonitis	pneumonitis	NOUN
dti-1420	137	19	in	in	ADP
dti-1420	137	20	patients	patient	NOUN
dti-1420	137	21	with	with	ADP
dti-1420	137	22	disseminated	disseminate	VERB
dti-1420	137	23	extranodal	extranodal	ADJ
dti-1420	137	24	marginal	marginal	ADJ
dti-1420	137	25	zone	zone	NOUN
dti-1420	137	26	b	b	NOUN
dti-1420	137	27	cell	cell	NOUN
dti-1420	137	28	lymphoma	lymphoma	NOUN
dti-1420	137	29	.	.	PUNCT
dti-1420	138	1	yonsei	yonsei	PROPN
dti-1420	138	2	med	med	PROPN
dti-1420	138	3	j.	j.	PROPN
dti-1420	138	4	2008;49:155–158	2008;49:155–158	PROPN
dti-1420	138	5	.	.	PUNCT
dti-1420	139	1	18	18	NUM
dti-1420	139	2	.	.	PUNCT
dti-1420	139	3	nishino	nishino	PROPN
dti-1420	139	4	m	m	PROPN
dti-1420	139	5	,	,	PUNCT
dti-1420	139	6	sholl	sholl	PROPN
dti-1420	139	7	lm	lm	PROPN
dti-1420	139	8	,	,	PUNCT
dti-1420	139	9	hodi	hodi	PROPN
dti-1420	139	10	fs	fs	PROPN
dti-1420	139	11	,	,	PUNCT
dti-1420	139	12	et	et	PROPN
dti-1420	139	13	al	al	PROPN
dti-1420	139	14	.	.	PUNCT
dti-1420	139	15	anti	anti	ADJ
dti-1420	139	16	-	-	ADJ
dti-1420	139	17	pd-1	pd-1	ADV
dti-1420	139	18	-	-	PUNCT
dti-1420	139	19	related	relate	VERB
dti-1420	139	20	pneumonitis	pneumonitis	NOUN
dti-1420	139	21	during	during	ADP
dti-1420	139	22	cancer	cancer	NOUN
dti-1420	139	23	immunotherapy	immunotherapy	NOUN
dti-1420	139	24	.	.	PUNCT
dti-1420	140	1	n	n	PROPN
dti-1420	140	2	engl	engl	PROPN
dti-1420	140	3	j	j	PROPN
dti-1420	140	4	med	med	PROPN
dti-1420	140	5	.	.	PUNCT
dti-1420	140	6	2015;373:288–290	2015;373:288–290	NUM
dti-1420	140	7	.	.	PUNCT
dti-1420	141	1	19	19	NUM
dti-1420	141	2	.	.	PUNCT
dti-1420	142	1	nakashima	nakashima	PROPN
dti-1420	142	2	k	k	PROPN
dti-1420	142	3	,	,	PUNCT
dti-1420	142	4	naito	naito	PROPN
dti-1420	142	5	t	t	PROPN
dti-1420	142	6	,	,	PUNCT
dti-1420	142	7	omori	omori	PROPN
dti-1420	142	8	s	s	PROPN
dti-1420	142	9	,	,	PUNCT
dti-1420	142	10	et	et	PROPN
dti-1420	142	11	al	al	PROPN
dti-1420	142	12	.	.	PUNCT
dti-1420	142	13	organizing	organize	VERB
dti-1420	142	14	pneumonia	pneumonia	NOUN
dti-1420	142	15	induced	induce	VERB
dti-1420	142	16	by	by	ADP
dti-1420	142	17	nivolumab	nivolumab	NOUN
dti-1420	142	18	in	in	ADP
dti-1420	142	19	a	a	DET
dti-1420	142	20	patient	patient	NOUN
dti-1420	142	21	with	with	ADP
dti-1420	142	22	metastatic	metastatic	ADJ
dti-1420	142	23	melanoma	melanoma	NOUN
dti-1420	142	24	.	.	PUNCT
dti-1420	143	1	j	j	PROPN
dti-1420	143	2	thorac	thorac	PROPN
dti-1420	143	3	oncol	oncol	ADJ
dti-1420	143	4	.	.	PUNCT
dti-1420	144	1	2016;11(3	2016;11(3	NUM
dti-1420	144	2	):	):	PUNCT
dti-1420	144	3	432–433	432–433	NUM
dti-1420	144	4	.	.	PUNCT
dti-1420	144	5	http://www.la-press.com	http://www.la-press.com	X
dti-1420	144	6	http://www.la-press.com/drug-target-insights-journal-j23	http://www.la-press.com/drug-target-insights-journal-j23	PROPN